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Abstract: Type 2 diabetes (T2D), which has currently become a global pandemic, is a 
metabolic disease largely characterised by impaired insulin secretion and action. Significant 
progress has been made in understanding T2D aetiology and pathogenesis, which is discussed 
in this review. Extrapancreatic pathology is also summarised, which demonstrates the highly 
multifactorial nature of T2D. Glucagon-like peptide (GLP)-1 is an incretin hormone respon-
sible for augmenting insulin secretion from pancreatic beta-cells during the postprandial 
period. Given that native GLP-1 has a very short half-life, GLP-1 mimetics with a much 
longer half-life have been developed, which are currently an effective treatment option for T2D 
by enhancing insulin secretion in patients. Interestingly, there is continual emerging evidence 
that these therapies alleviate some of the post-diagnosis complications of T2D. Additionally, 
these therapies have been shown to induce weight loss in patients, suggesting they could be an 
alternative to bariatric surgery, a procedure associated with numerous complications. Current 
GLP-1-based therapies all act as orthosteric agonists for the GLP-1 receptor (GLP-1R). 
Interestingly, it has emerged that GLP-1R also has allosteric binding sites and agonists have 
been developed for these sites to test their therapeutic potential. Recent studies have also 
demonstrated the potential of bi- and tri-agonists, which target multiple hormonal receptors 
including GLP-1R, to more effectively treat T2D. Improved understanding of T2D aetiology/ 
pathogenesis, coupled with the further elucidation of both GLP-1 activity/targets and GLP-1R 
mechanisms of activation via different agonists, will likely provide better insight into the 
therapeutic potential of GLP-1-based therapies to treat T2D. 
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Introduction
Type 2 diabetes (T2D) is the most common and clinically important metabolic disorder 
which has become a global pandemic in recent decades and a major healthcare burden 
worldwide. In 2013, there were an estimated 382 million patients with diabetes 
globally.1 Concerningly, the T2D incidence continues to increase, and it is projected 
that there will be >590 million patients diagnosed with this condition by 2035.1,2 The 
World Health Organisation (WHO) defines diabetes as a “metabolic disorder of multi-
ple aetiology characterised by chronic hyperglycaemia with disturbance of carbohy-
drate, fat, and protein metabolism resulting from defects in insulin secretion, insulin 
action, or both.”3 The most prevalent form of diabetes is type 2, as an estimated 90% of 
diabetes patients are diagnosed with this form,2 and the majority of the remaining 10% 
of patients have type 1 diabetes (T1D), although there are other rare types.4 T2D is 
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largely caused by impaired insulin production and secretion 
by pancreatic beta-cells, as well as peripheral tissue insulin 
resistance.5,6 Given that ~90% of patients are obese or over-
weight at T2D diagnosis, the aetiology of T2D is largely 
thought to be linked to diets involving excessive nutrient 
consumption combined with insufficient energy 
expenditure.7 There are a range of effective treatments that 
reduce hyperglycaemia in T2D patients, which mediate their 
effects by improving insulin secretion or decreasing periph-
eral tissue insulin resistance.8 Despite this, post-diagnosis 
complications, especially long-term complications, are pre-
valent globally. As a result, diabetes remains a leading cause 
of blindness, end-stage renal disease, lower limb amputation 
and cardiovascular disease.3
T2D and obesity have such an interdependent relation-
ship that the term “diabesity” has been coined.9 In recent 
decades, the number of people with T2D has more than 
doubled, and the increased global burden of T2D is 
thought to be largely due to an increase in obesity.9,10 
Obesity has become a global pandemic over recent dec-
ades. Weight loss is associated with an improved prognosis 
for overweight T2D patients and obese individuals. Better 
glycaemic control has been reported in T2D patients who 
have lost weight, and excess body weight is associated 
with the risk of cardiometabolic complications, which are 
major causes of morbidity and mortality in T2D and obese 
individuals.11,12 Bariatric surgery has proven to be an 
effective treatment for diabesity, but it is expensive and 
there are numerous post-surgery complications: for exam-
ple, vomiting and dumping syndrome, iron and B12 defi-
ciency, and secondary hyperparathyroidism.13 GLP-1 
analogues (eg liraglutide and exenatide) are used to treat 
T2D as they promote insulin secretion and induce weight 
loss.3 Since the GLP-1 receptor (GLP-1R) agonists are 
effective in treating diabesity, they could be pharmacolo-
gical alternatives to bariatric surgery but without the post- 
surgery complications.3,13,14
The current literature on T2D epidemiology, aetiology, 
pathogenesis and treatment is discussed in this review.
Obesity
Obesity is caused by excessive energy intake and subse-
quent storage coupled with insufficient energy expenditure 
resulting in weight gain. It has become a huge healthcare 
concern over the last few decades, especially in developed 
countries. However, in some obese individuals, excessive 
dietary intake may have a genetic aetiology, such as leptin 
deficiency.15–17 Obese individuals have a BMI of ≥30 kg/ 
m2, and individuals with a BMI of ≥25 and <30 are 
classified as overweight.16 Obesity and overweight inci-
dences have more than doubled since 1980, giving rise to 
>2.1 billion individuals with a BMI of >25 globally, as 
stated by the WHO.15,18 The WHO estimated that there 
were ~600 million obese individuals in 2014, and this 
number will continue to rise in the future.18 Obesity is 
associated with an increased risk for T2D, hypertension, 
dyslipidaemia, cardiovascular diseases, musculoskeletal 
disorders (such as osteoarthritis), certain types of cancer, 
and premature mortality.19,20 It is well established that 
there is a generally directly proportional relationship 
between BMI and both fasting and postprandial insulin 
levels.21,22 A similar relationship also exists between 
BMI and the degree of insulin resistance.22 The hyperin-
sulinemia associated with rising BMI is necessary to over-
come insulin resistance and maintain normoglycemia.22 
Not all obese individuals develop insulin resistance 
though;23 one study reported that 19, 34 and 60% of 
individuals with a BMI of <30, ≥30–35 and >35, respec-
tively, were insulin resistant.22 Insulin hypersecretion also 
becomes more frequent with increasing BMI;24 28, 49 and 
80% of individuals with a BMI of <30, >30–35 and >35, 
respectively, exhibited insulin hypersecretion.22 Of the 2.1 
billion individuals that are obese or overweight <25% have 
been diagnosed with T2D.1,18 The rise in T2D over the last 
few decades is generally thought to be attributed to an 
increase in the percentage of overweight individuals in the 
global population.3,25 Figure 1 shows how the percentage 
of overweight and obese individuals in the population vary 
between countries.
Type 2 Diabetes
Diabetes mellitus was first reported over 3000 years ago in 
an Egyptian manuscript.26 However, it was not until 1936 
that the distinction between T1D and T2D was made.27 T2D 
is by far the most common form of diabetes and accounts 
for ~90% of diabetes cases.2,7 T2D is a chronic metabolic 
complex multifactorial disease, involving many organs, that 
has become a global pandemic in recent decades.1,28 T2D is 
characterised by pancreatic beta-cell dysfunction, increased 
pancreatic alpha-cell function, and peripheral tissue insulin 
resistance. These alterations result in (1) hyperglycaemia 
due to impaired peripheral glucose uptake, (2) dyslipidae-
mia (hypertriglyceridemia and low high-density lipoprotein 
[HDL]-cholesterol) due to impaired peripheral fat uptake, 
(3) impaired amino acid uptake and ATP production into 
peripheral tissues, such as skeletal muscle, due to the 
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impaired nutrient uptake, and (4) increased glucagon pro-
duction, which further amplifies hyperglycaemia and 
hyperlipidaemia.29–32 T2D is thought to be largely pro-
voked by diets involving excessive nutrient consumption, 
as ~90% of patients are obese or overweight in western 
countries.3,9,16,33 In contrast to that observed in western 
countries, a study in China found that 50.3% of T2D 
patients were not overweight,34 and other Asian countries 
also have a high percentage of T2D patients with a BMI of 
<25.35 It has become clear that genetic factors also play a 
role in conferring susceptibility, although no important risk 
genes have yet been identified.36,37 T2D is considered to be 
a heterogeneous disease as the severity of insulin defi-
ciency, treatment requirements and prognosis varies 
between patients.38,39
Although treatments are available, diabetes remains a 
leading cause of blindness, end-stage renal disease, lower 
limb amputation and cardiovascular disease.40 One study in 
the UK found that 48.9% of amputations from 2007 to 2010 
were carried out on people with diabetes and diabetes con-
ferred a 23.3x risk for amputations.41 Additionally, diabetic 
patients also usually exhibit impaired wound healing, sus-
ceptibility to infection, neuropathology and impotence.3 
T2D has also been identified as a risk factor for 
Alzheimer’s and Parkinson’s diseases.42,43 Cardiovascular 
disease (CVD) accounts for 75% of all related deaths in 
diabetic patients and on average individuals with T2D have 
an increased risk of shorter life expectancy.44,45 There are a 
range of treatments available which improve insulin secre-
tion and/or decrease peripheral tissue insulin resistance, 
which reduces hyperglycaemia.46,47 However, maintaining 
glycaemic control in patients is no easy task, as hypo- or 
hyperglycaemia can result from administration of the cur-
rently available treatments resulting in either too much or 
not enough, respectively, of an anti-hyperglycaemic effect.-
3,48 Regardless of the treatment regime, longitudinal studies 
in humans have demonstrated that beta-cell function gen-
erally deteriorates over time.49,50 It has been postulated that 
chronic hyperglycaemia and dyslipidaemia lead to a pro-
gressive decline in beta-cell function post-diagnosis.50
Epidemiology of T2D
It has been estimated that there were ~382 million T2D 
patients globally in 2013 and that number has more than 
doubled in the last few decades.1 The incidence and preva-
lence of T2D continue to increase. By 2035, it is estimated that 
there will be >590 million T2D people diagnosed.1,2 Although 
the prevalence and incidence of T2D vary between countries, 
T2D is still considered to be a global disease.28 T2D used to be 
considered as a disease induced by ‘western lifestyles’ (high- 
calorie diets and sedentary lifestyles).3 Interestingly, the rise in 
prevalence of T2D is estimated to be almost 4x as high in 
developing as in developed countries.1,25,51 This is thought to 
be due to developing countries adopting ‘western lifestyles’ 
and the increase in obesity and the number of people being 
overweight in their populations.1,28,52 In general, the age group 
with the highest risk of developing T2D is 40–60 years in 
developed countries and 60+ years in developing countries.53 
Although T2D is considered to be a disease associated with 
adulthood and the incidence of T2D increases with age, it is 
becoming more common for children to be affected.54,55 It is, 
however, likely that the number of cases of individuals 
Figure 1 Variation in the percentage of obese and overweight individuals over 18 years of age in the population between different countries in 2016.325 Values displayed are 
an average of the male and female percentage of the population for each country, which were taken from the WHO data.325
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diagnosed with T1D in adulthood is underestimated: it has 
been speculated that 5–15% of adult patients are misdiagnosed 
as having T2D when they may actually have T1D, which is 
currently an area of controversy in the literature.56,57
Diabetes in young people was previously thought to be 
T1D.58 Until the early 1990s, it was rare for paediatric 
centres to have T2D patients. However, this has drastically 
changed since the late 1990s onwards with paediatric T2D 
accounting for up to 45% of newly diagnosed paediatric 
diabetes cases in the USA. The ”youth T2D” is not just a 
phenomenon limited to the USA.59 Staggeringly, 80% of 
all new diabetes cases in Japan in children and adolescents 
were reported as T2D and other countries have also 
reported an increase in youth T2D.60 However, many 
studies from Europe have reported that youth T2D is 
much rarer, accounting for only 1–2% of all diabetes 
mellitus cases.55,60 China has the highest number of T2D 
patients (~98 million) and India has the second-highest 
(around 65 million).1 The USA was estimated to have 
around 24.4 million T2D patients in 2013.61 Tokelau has 
Figure 2 (A) The varying estimated prevalence of T2D in 2013 and projections for 2035, between ages 20–79 years.1 (B) The varying estimated prevalence of T2D in 2019 
and projections for 2030 and 2045, between ages 20–79 years.62 The numbers above are the values for each country, indicating the percentage increase of diabetes patients 
from 2013 to 2035 (A) or from 2019 to 2045 (B) for any given country, rounded to the nearest whole number. Data from these studies.1,62
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been reported in 2013 as the country with the greatest 
prevalence of T2D (37.5%) in the national population. 
The Federated States of Micronesia, the Marshall Islands, 
and Kiribati all have T2D prevalence rates in their national 
populations of 35, 34.9 and 28.8%, respectively.1 All other 
countries had T2D national population prevalence rates of 
under 26% in 2013.1 Globally, the number of people with 
diabetes was estimated to be 285, 366, 382, 415 and 425 
million in the years 2009, 2011, 2013, 2015 and 2017, 
respectively.62 Figure 2 shows how T2D prevalence varied 
between countries in 2013 and 2019, and predictions for 
future data on T2D prevalence are also shown.1,62
Diabetes was considered to be rare in the first half of 
the twentieth century in the USA; less than 1% of the 
population was diagnosed with diabetes in 1958.63,64 
However, both the incidence and prevalence of T2D 
increased throughout the second half of the 20th century 
in developed countries, becoming an epidemic towards 
the end of the century and remaining as such into the 
21st century.1,63 Over recent decades, T2D incidence 
and prevalence have also increased in developing coun-
tries, becoming a comparable health burden in these 
countries. In 1980, <1% of China’s population had dia-
betes but this increased to almost 10% by 2008.25 In 
urban areas of South India, almost 20% of the 
population was estimated to be affected by diabetes in 
2008.65 In 2014, a study revealed that 46% of newly 
diagnosed T2D patients in India were under 40 years of 
age,66 which is a contrast with the notion that patients in 
developing countries are usually over 60.53 T2D inci-
dence and prevalence have continued to increase glob-
ally in the 21st century as well. By 2045, it has been 
estimated that there will be over 700 million T2D 
patients worldwide.1,62 However, as highlighted in 
Tables 1 and 2, the future increase in the number of 
T2D patients will be partly due to the rise in the global 
population and not just increasing incidence.1
Studies have demonstrated that the incidence of T2D 
potently increased globally in the latter half of the 20th century 
(especially paediatric cases), and one study even reported the 
incidence of diabetes rose from 2.6 to 9.4% between 1980 and 
1988 in the USA.59,67 Although life expectancy has generally 
increased globally over the last few decades, this does not fully 
explain the rise in T2D incidence and prevalence given the 
drastic increase in childhood cases, but it likely accounts for at 
least part of the rise in T2D in developing countries where 
patients are generally aged 60+ years.47 Globally, it was esti-
mated that diabetes accounted for ~12% of health expenditures 
in 2010 (at least $376 billion), and the healthcare cost will 
continue to rise to ~$490 billion in 2030.28 Many developing 
Table 1 Variation of T2D Prevalence Between Global Regions in 2013 and Projections for 2035


















Africa 407.8 19.8 5.7 775.5 41.5 6








347.5 34.6 10.9 583.7 67.9 11.3
South-East 
Asia




300.5 24.1 8.2 394.2 38.5 8.2
Western 
Pacific
1613.2 138.2 8.1 1818.2 201.8 8.4
Notes: Adapted from Diabetes Res Clin Pract, 103(2), Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 
2013 and projections for 2035. Diabetes Res Clin Pract. 137–149. Copyright (2014), with permission from Elsevier.1
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countries do not have adequate infrastructure to treat this 
pandemic, meaning that diabetes is a serious concern for the 
future.28 Additionally, there is continuing emerging evidence 
that the prevalence and incidence of diabetes are likely higher 
in developing countries than currently documented due to 
undiagnosed diabetes. Studies conducted in Africa estimated 
that 18% of adult diabetes patients in Libya and 75% of adult 
diabetes patients in Tunisia were undiagnosed.68 Generally, 
the incidence of T2D continues to increase globally but at a 
steadier rate than in previous decades - this statement could be 
incorrect due to the uncertain global prevalence and incidence 
of undiagnosed diabetes.1 The rise in the prevalence and 
incidence of T2D throughout the 20th and 21st centuries glob-
ally currently classifies this disease as a global pandemic; the 
rise in this increase is generally thought to be due to an 
increase in the percentage of the global population being over-
weight accompanied by individuals adopting more sedentary 
lifestyles.28
Aetiology
Many risk factors have been identified for T2D.3,69 The main 
risk factor is obesity as being obese can increase the risk of 
developing T2D by 90-fold, and the majority of patients are 
overweight or obese.9,15 T2D risk is positively correlated 
with increasing BMI, and the risk rises exponentially with 
increasing BMI above 30.15 In Western countries, it has been 
estimated that ~50% of T2D patients have a BMI of >30 and 
30–40% have a BMI of 25–30.70 However, in some Asian 
countries, ~50% of patients are not overweight.34,35 
Surprisingly, underweight T2D patients have even been 
reported.71,72 Increased deposition of fat in the ectopic 
regions of the body (particularly visceral fat) also increases 
T2D risk by more than double.3,73 Genetics are known to 
play an important role in T1D but this is also the case for 
T2D.37,74 The concordance rate between monozygotic twins 
with T2D is higher (around 70%) compared with T1D 
(between 30 and 50%), and additionally, the lifetime risk of 
individuals for developing T2D with one affected parent is 
40% and almost 70% if both parents are affected - these 
observations suggest that genetics play an important role in 
T2D susceptibility.75,76 Concordance rates between dizygotic 
twins with T2D (between 20 and 30%) are also higher than 
T1D (around 10%).7,75,76 However, the highest odds ratio 
reported for a risk locus for T2D is 1.57 – this implies that 
more currently untested variants underlie T2D 
susceptibility.37 The increased risk of developing T2D for 
relatives of type 2 diabetic patients may be due to them 
sharing similar diets and lifestyles as well as genetics.7,77 
Table 2 Variation of T2D Prevalence Between Global Regions in 2019 and Projections for 2030 and 2045
Region Diabetes Patients 




















Africa 19.4 4.7 28.6 5.1 47.1 5.2








54.8 12.2 76 13.3 107.6 13.9
South-East 
Asia




31.6 8.5 40.2 9.5 49.1 9.9
Western 
Pacific
162.2 11.4 196.5 12.4 212.2 12.8
Notes: Adapted from Diabetes Res Clin Pract, 2, Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 
2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. 157, copyright (2019), with permission from Elsevier.62
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One study demonstrated the importance of genetics in T2D 
susceptibility independently of the diet as there was a higher 
prevalence of the disease in the twin population compared to 
the singleton population77– both populations had similar 
average BMI scores (26.1–26.3) with comparable standard 
deviation values (3.9–4.7). A cohort study found that alcohol 
and smoking also increased the risk of T2D, even in indivi-
duals who were classified as having low-risk diet and physi-
cal activity profiles.78
Interestingly, longitudinal studies have demonstrated 
that “psychological stress-related circumstances” (such as 
stressful working conditions) or mental health problems 
(such as depression) increase the risk of T2D.79 Globally, 
more males are diagnosed with T2D than females, and 14 
million more men were diagnosed with this disease than the 
number of women in 2013.80 Evidence demonstrates that 
adult men are at higher risk of T2D than women, which is at 
least partly thought to be due to differential adiposity sto-
rage patterns in men.81 Studies have shown that men with 
T2D are more likely to develop CVD, but women with T2D 
who do develop CVD are more likely to have a worse 
prognosis, which is thought to be at least partly due to 
men being more likely to achieve medical targets in T2D 
(such as desirable plasma glucose control and blood 
pressure).80,81 The seasonality of T2D onset is not well 
studied, but a study conducted in Hungary found that sea-
sonality followed a sinusoidal pattern; the peak month was 
March, and the trough month was August.82 A recent study 
also found that Chinese individuals born outside of summer 
had a 9% increased chance of developing adult T2D than 
individuals born in summer.83 Environmental changes over 
the last few decades could also play a role in T2D aetiology 
due to the use of pesticides, drugs and food additives in food 
processing and packaging.84 However, minimal evidence 
exists linking T2D aetiology to altered food processing/ 
packaging in recent decades.84 Some environmental pollu-
tants have been shown to alter β-cell function, and the best 
example is bisphenol A (used in food container manufactur-
ing), which can cause impaired beta-cell function in 
animals.85 However, it has not yet been determined whether 
prevailing environmental concentrations of these types of 
compounds can be a risk factor for diabetes.84 Associations 
have been made between certain pathogens and T2D risk: 
herpes simplex virus type 1 and hepatitis C virus are risk 
factors for T2D, although it is not clear how this can be 
mechanistically explained.86,87 However, it has been estab-
lished that hepatitis C promotes insulin resistance in the 
liver, which is thought to increase T2D risk.88,89 If this is the 
case, then this implies that T2D manifestation can be 
initiated by insulin resistance in the liver alone, which 
therefore suggests that the liver may play a much more 
important role in T2D aetiology/pathogenesis than is cur-
rently thought.
Pathogenesis
The main focus here is the current and future therapeutic 
potential of modulation of GLP-1R activity in T2D, but the 
altered activity of hormones involved in metabolic home-
ostasis observed in T2D are also discussed, as well as other 
factors, such as the nervous system and uncoupling protein 
2 (UCP2), to highlight the complexity of its pathogenesis.
Typically, T2D does not manifest acutely in individuals 
but is preceded by an insidious phase of prediabetes.90 
Prediabetes is characterised by raised blood glucose levels 
(fasting plasma glucose levels of 6.1–6.9 mmol/L and two 
hours post glucose ingestion levels between 7.8–11 mmol/L) 
due to declining islet beta-cell mass and function but not 
enough to warrant a diagnosis of T2D.90,91 Patients with 
prediabetes are asymptomatic but90 ~5–10% progress to 
T2D each year.90,91 Studies have demonstrated that weight 
loss and exercise can usually delay progression to T2D, or 
even prevent T2D from manifesting; lifestyle interventions 
reduce the risk of T2D progression in 40–70% of adults with 
prediabetes.91,92 It has been estimated that ~70% of indivi-
duals with persistent prediabetes will eventually develop 
T2D, and that >470 million people will have prediabetes by 
2030.91 Progressing to T2D is characterised by blood glucose 
levels of >7 mmol/L during fasting and a two hours post 
glucose ingestion reading of >11 mmol/L.90,93 The consensus 
in the literature is that T2D clinical manifestation is provoked 
by peripheral tissue insulin resistance, which is in turn, 
usually induced by obesity.6,30,94 Obesity is characterised 
by elevated levels of cytokines and fatty acids, and it is 
thought that elevated levels of both provoke insulin 
resistance.94 However, it has still not been determined how 
this occurs mechanistically.95 Following the induction of 
insulin resistance, islet beta-cells can maintain normoglycae-
mia and metabolic homeostasis by increasing their secretion 
of insulin and/or by increasing their number.49,96,97 Obesity 
has been estimated to induce an ~50% increase in islet beta- 
cell volume due to increased neogenesis.49 However, over 
time islet beta-cells are seemingly unable to compensate for 
the insulin resistance and their ability to secrete insulin 
decreases and many islet beta-cells undergo apoptosis, 
which is thought to be a result of a variety of stressors, 
such as increased insulin demand, oxidative, endoplasmic 
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reticulum, dyslipidemic, amyloidal, and inflammatory 
stress.98,99 The characteristic consequences of beta-cell 
pathology during T2D include impaired first-phase insulin 
secretion, ongoing insufficient insulin secretion to promote 
normolipidaemia (normal triglyceride levels, normal LDL 
cholesterol, and normal HDL-cholesterol) and normoglycae-
mia, dysfunctional glucose-sensing, and an increased propor-
tion of proinsulin secretion.98
During prediabetes, pancreatic beta-cell number and 
function decline slowly, usually over a few years before 
T2D manifests.91 It has been reported that the decline in 
islet beta-cell function can begin an average of 12 years 
before T2D diagnosis.49 Interestingly, there have been 
reports of individuals who do not progress to T1D for 
>10 years despite persistent islet autoimmunity (slow 
progressors).100 This demonstrates that the rate of islet 
beta-cell death can vary greatly between individuals before 
T1D or T2D diagnosis, enabling some individuals to 
remain disease-free for longer, possibly by similar 
mechanisms. The gradual decline in islet beta-cell number 
and function results in insulin levels becoming too low to 
promote metabolic homeostasis and T2D results.49,91 
Hyperproinsulinemia has been reported in both T2D 
patients and individuals with prediabetes, suggesting that 
defective islet beta-cell insulin processing is integral to the 
early stages of disease pathology.101,102 In healthy sub-
jects, proinsulin accounts for up to 20% of the insulin 
levels in circulation, but in T2D this value can reach up 
to 50% and total proinsulin levels have shown to be higher 
in T2D patients than healthy controls, which suggests that 
dysfunctional processing and secretion of insulin by the 
remaining islet beta-cell population further contributes to 
the decreased insulin levels observed in this disease.101,103 
Symptoms of T2D manifest when insulin levels become 
too low to prevent hyperglycaemia, which includes dehy-
dration, excessive thirst, increased susceptibility to infec-
tion, excessive urination, lethargy and blurred vision.3,47 
Chronic superphysiological glucose concentrations also 
Figure 3 Comparing healthy and type 2 diabetic phenotypes. In healthy individuals, insulin is produced and secreted by beta-cells in the islets of Langerhans (found in the 
pancreas) when blood glucose levels are above 5mM. Beta-cells are the most abundant cell type in the islets (~70%) and alpha-cells (responsible for glucagon secretion) are 
the second most abundant (~20%). Insulin then binds to the insulin receptor (IR), which allows uptake of glucose into tissues by inducing translocation of GLUT4 receptors 
from intracellular vesicles to the plasma membrane. GLUT4 is primarily found in adipose tissue as well as skeletal and cardiac muscle. Glucose is then transported into the 
cell by GLUT4 from the bloodstream and catabolised in the cell for ATP production, which provides the fuel for intracellular processes, or glucose can be converted to 
either glycogen or fat for fuel storage after uptake. In individuals with T2D, many islet beta-cells have undergone apoptosis and the function of the surviving cells is impaired, 
which results in markedly reduced insulin levels in circulation. Additionally, peripheral tissue insulin resistance impairs the action of insulin, resulting in reduced uptake of 
glucose from circulation, as a result of decreased GLUT4 translocation to the membrane. Reduced insulin levels and action result in hyperglycaemia and hyperlipidaemia, and 
subsequent T2D associated symptoms manifest in the patient. Inappropriate glucagon secretion, diminished incretin hormone action, increased proinsulin secretion, 
impaired pancreatic islet neural regulation, and islet amyloid deposition are also characteristic of T2D. This figure and information in its legend are with data adapted from 
these studies.105,106,111,326–328
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negatively affect the ability of islet beta-cells to secrete 
insulin, which further worsens hyperglycaemia and pro-
motes T2D.104 Peripheral tissues dependent on insulin to 
uptake nutrients from circulation can no longer do so to 
the same extent as before T2D.47,105 Hence, peripheral 
tissues adapt to rely on fat and catabolism of intracellular 
stored macromolecules, such as proteins, to generate the 
ATP they need.3,32 This results in weight loss (due to the 
breaking down of macromolecules), excessive eating and 
lethargy.3,32,105,106 Figure 3 compares healthy and type 2 
diabetic phenotypes.
It has been demonstrated that the insulin released dur-
ing the early and late postprandial period by T2D patients 
is ~25 and 40%, respectively, of that produced by healthy 
individuals with a similar BMI.107 Fasting insulin levels in 
T2D patients are ~50% of that observed in healthy subjects 
with a similar BMI,107 demonstrating that T2D has a more 
significant effect on impairing the insulin response during 
the postprandial period in the early stages of the disease. 
Interestingly, insulin levels are higher in diabesity patients 
than in normal-weight T2D subjects,21 implying that the 
islet beta-cell pathology is more severe in the latter group 
and that peripheral tissue insulin resistance contributes 
more to the disease phenotype in overweight T2D patients. 
Although it is known that the postprandial insulin response 
is similarly impaired in overweight and normal-weight 
T2D patients (determined by measuring the increase in 
insulin levels in comparison to fasting levels), absolute 
insulin levels are higher in overweight patients compared 
to disease-free normal-weight subjects, during both fasting 
and the postprandial period,21 which strongly suggests that 
in overweight T2D subjects peripheral tissue insulin resis-
tance is central to the clinical manifestation of this disease. 
T1D is more “severe” than T2D, as ~90% of beta-cells are 
destroyed by autoimmunity, which results in vastly 
reduced insulin levels.108 Insulin treatment is essential 
for survival in T1D, as the absolute insulin deficiency 
results in the induction of ketoacidosis in an attempt to 
provide tissues dependent on insulin with adequate fuel.106 
Ketoacidosis is necessary during starvation to provide fuel 
to tissues when there is no adequate nutrient supply.109 
However, prolonged ketoacidosis is fatal due to the low-
ering of blood pH, which is why T1D is considered to be a 
deadlier form of diabetes than type 2, although a subset of 
T2D patients can develop ketoacidosis.106,110 Although 
ketoacidosis is largely considered to be a pathological 
response, fatality is inevitable under these circumstances, 
as impaired ATP production is fatal.32,106,111
It has been firmly established that T2D is caused by the 
dysfunctional exocrine function of the pancreas, and periph-
eral insulin resistance is a requisite precursor for the devel-
opment of this disease.105,112 Skeletal muscle insulin 
resistance has been associated with intracellular lipid 
accumulation.94 However, endurance-trained insulin-sensi-
tive athletes may have as much, if not more, lipid content in 
their skeletal muscles as insulin-resistant T2D patients.113,114 
Thus, it seems that a high rate of ATP turnover in athletes 
prevents skeletal muscle insulin resistance, but a decreased 
demand for ATP in typically sedentary obese individuals with 
and without T2D induces insulin resistance.94 It is reasonable 
to assume that insulin resistance in obese individuals without 
T2D may be desirable in skeletal muscle that has an abun-
dance of stored nutrients and a low rate of ATP turnover, as 
the tissue’s ATP demands are met and hypertrophy would 
result from any further nutrient uptake. However, it is correct 
to state that peripheral tissue insulin resistance is pathological 
in T2D as it contributes to the disease phenotype.30,47 The 
insulin resistance in peripheral and hepatic tissues is present 
in obese and non-obese T2D patients, but not to the same 
extent.115 Studies have shown that BMI is correlated to the 
degree of insulin resistance in Korean patients, even within 
the non-obese range.116 Weight loss has been shown to 
decrease insulin resistance in both obese T2D patients and 
obese T2D-free individuals, suggesting that insulin resistance 
is related to increased nutrient storage.117 Interestingly, insu-
lin resistance is also observed in a proportion of T2D-free 
individuals within the normal weight range (BMI>18.5–25) 
and is reasonable to assume that this is pathological as, in 
theory, peripheral tissues are not at risk of hypertrophy due to 
insulin action and require continual nutrient influx to main-
tain ATP supply to meet their metabolic demands, as these 
individuals are not overweight and do not have an abundance 
of stored nutrients within their tissues.23,118 One study 
demonstrated that normalisation of both beta-cell function 
and hepatic insulin sensitivity in T2D patients was achieved 
by 8 weeks of dietary energy restriction alone (600 kcal a 
day), accompanied by decreased pancreatic and liver triacyl-
glycerol stores.119 After cessation of the low-calorie diet and 
returning to a normal diet for 12 weeks, 7 out of 10 partici-
pants remained in remission. Given that lipid accumulation 
both in and around the pancreas is associated with beta-cell 
pathology and confers T2D risk,120 the observation that T2D 
remission was accompanied by a decrease in pancreatic fat 
content suggests that increased pancreatic fat storage is an 
important component of T2D aetiology/pathogenesis. In 
healthy individuals, insulin sensitivity varies naturally, 
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which is thought to be beneficial for promoting metabolic 
homeostasis.121–123 The general consensus in the literature is 
that chronic insulin resistance, induced by obesity, is thought 
to be pathological overall in the metabolic syndrome, which 
is a syndrome characterised by a range of disorders that 
collectively predispose risk to T2D and cardiovascular 
pathology.94
A study examined pancreatic tissue from 124 autop-
sies: 91 obese cases (BMI >27kg/m2; 41 with T2D, 15 
with impaired fasting glucose [IFG], and 35 non-diabetic 
subjects) and 33 lean cases (BMI <25kg/m2; 16 types 2 
diabetic and 17 non-diabetic subjects.124 Obese humans 
with IFG and T2D had a 43 and 60%, respectively, 
decrease in islet beta-cell volume compared to obese non-
diabetic individuals. This decrease in islet beta-cell 
volume in obese T2D patients was found to be due to a 
decreased number of islet beta-cells, and interestingly the 
volumes of these cells were found to be similar between 
non-diabetic obese and diabetic obese individuals. The 
frequency of islet beta-cell replication was found to be 
similar between obese nondiabetic and T2D patients. 
However, it was estimated that there was an ~3-fold 
increase in apoptosis in obese T2D individuals. The major-
ity of diabesity cases were found to have islet amyloid in 
their islets (~80%), whereas only ~10% of obese indivi-
duals without T2D had amyloid deposits. Amyloid depos-
its had a similar prevalence in IFG obese individuals to 
that observed in T2D-free obese individuals. Islet beta-cell 
dysfunction in diabesity patients is therefore attributed to 
increased rates of apoptosis and amyloid deposition, and 
not to rates of replication and new islet formation as this is 
similar to non-diabetic controls.
Currently, why individuals of normal weight develop 
T2D is largely elusive, but pathogenesis appears to be 
similar to diabesity patients, although there are some strik-
ing differences according to the study conducted in 
2003.124 Islet beta-cell mass was shown to be decreased 
in lean T2D patients by ~41% in comparison to lean T2D- 
free controls, due to a decreased number of these cells. 
Islet amyloid was present in 88% of lean T2D patients but 
only 13% of lean healthy controls. New islet formation 
and beta-cell replication were similar between lean T2D 
patients and lean T2D-free individuals, but the frequency 
of beta-cell apoptosis was increased by 10-fold in lean 
T2D patients. Hence, lean T2D is also characterised by 
an increased rate of beta-cell apoptosis with a normal, but 
too slow a replication rate of these cells to restore their 
numbers to normal levels. It is not known if islet amyloid 
deposits are produced due to the chronic hyperglycaemia 
associated with this disease. It is also not clear if these 
deposits affect the prognosis of T2D.124,125
What has become clear is that islet amyloid deposits 
are very likely to be directly involved in the pathogenesis 
of T2D, although it has not been well established how 
mechanistically.124,126,127 Islet amyloid polypeptide 
(IAPP) (more commonly known as amylin) is co-secreted 
with insulin from islet beta-cells in healthy individuals 
during the fed state and acts as an anti-hyperglycaemic 
agent by decreasing gastric motility, promoting satiety and 
inhibiting glucagon secretion.128 The amylin analogue 
pramlintide is used for T1D and T2D treatment adjunct 
with insulin therapy in the USA if patients are not achiev-
ing adequate glucose control despite optimal insulin 
therapy.129 Virtually all T2D patients have IAPP-contain-
ing plaques in their islets.128 IAPP appearance was first 
noticed in the 1980s to correlate with hyperglycaemia in 
primates.130 Several lines of transgenic mice have been 
generated which produce human IAPP, and they were 
shown to have islet amyloid accumulation, increased 
beta-cell apoptosis, decreased beta-cell mass, impaired 
glucose tolerance, and some developed diabetes.128 The 
current consensus in the literature is that extracellular 
plaques of IAPP are not causative of beta-cell pathology, 
but rather intracellular oligomers of this protein observed 
in T2D patients (but not in T2D-free individuals) produce 
the cytotoxic effects.128,131 It has been elucidated that 
beta-cells are usually protected from IAPP oligomers by 
autophagy processes, so it seems that these processes are 
defective in prediabetes and T2D, which is likely pivotal 
for the pathogenesis of T2D.128,132 Both T1D and T2D 
manifest due to beta-cell apoptosis and the activated apop-
totic pathways are thought to share similarities, but the 
aetiology of apoptosis is different between the two 
diseases.133
Although obesity is a major risk factor for T2D, para-
doxically overweight and obese patients have been 
reported to have had a lower mortality rate than normal- 
weight patients due to cardiovascular pathology associated 
with T2D and this phenomenon was termed “the obesity 
paradox”.134,135 Furthermore, weight loss has been 
reported to increase mortality and morbidity in T2D and 
cardiovascular co-morbidity patients.136 Additionally, a 
study found that the risk of amputation in non-elderly 
diabetic men decreased with increasing body weight.137 
Peripheral and hepatic insulin resistance is present in 
obese and non-obese T2D patients, but not to the same 
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extent in non-obese subjects.115 Studies have shown that 
BMI is correlated to the degree of insulin resistance in 
Korean patients, even within the non-obese range.116 
Interestingly, a study from India found that fasting and 
postprandial plasma glucose levels were higher in T2D 
patients with a BMI <18.5.71 The aetiology of T2D 
patients with a BMI of under 25 is thought to be largely 
attributed to beta-cell dysfunction, which is thought to be 
greater than that observed in obese patients.71 A study 
conducted in Chicago found that glycaemic control was 
worse in T2D patients with a BMI of 18–25 than in 
individuals with a BMI of over 25, but these patients had 
lower insulin resistance.138 The study found that smoking 
and alcoholism confer an increased risk for non-obese 
T2D than obese T2D, chronic alcoholism induces islet 
beta-cell dysfunction and apoptosis.139 Strikingly, T2D 
has been shown to manifest in non-overweight individuals 
in the absence of insulin resistance, although this is 
thought to be rare.140 This implies that pancreatic exocrine 
dysfunction can induce T2D independent of both insulin 
resistance and a BMI>25. Whether or not weight loss in 
T2D patients with a BMI of under 25 improves prognosis 
has not been determined.71 It has been well established 
that Asians are at increased risk of non-overweight T2D. 
In Japan, more than 50% of patients have a BMI of under 
25, but they have more abdominal fat at the equivalent 
BMI to Caucasians.35,71
T2D is not only attributed to beta-cell dysfunction but 
also alpha-cell dysfunction.141,142 Pathologically high 
plasma concentrations of glucagon are observed in T1D, 
advanced T2D, and diabetic ketoacidosis.142 It is well estab-
lished that islet alpha-cell populations increase in T1D, 
whereas in T2D, patients can have alpha-cell numbers 
increased or unaltered.141 Paradoxically, T2D patients have 
increased levels of glucagon during the postprandial period, 
leading to augmentation of postprandial hyperglycaemia 
associated with impaired insulin secretion.142,143 Hence, it 
is correct to state that the behaviour of diabetic islet alpha- 
cells is different for healthy individuals, as an abundance of 
nutrients during the postprandial period prevents glucagon 
secretion in healthy individuals by raising ATP levels (as 
discussed earlier in this review).144 Therefore, in T2D, the 
islet alpha-cells must have altered biochemical pathways 
inducing altered mechanisms of glucagon secretion. Studies 
have estimated that postprandial hyperglucagonemia may 
contribute to ~50% of the pathological increase in plasma 
glucose levels after glucose ingestion.145–147 Interestingly, 
fasting hyperglucagonemia has been reported in some T2D 
patients with moderate glycaemic control, and glucagon 
levels are ~50% higher in diabetic subjects.146,148 The dys-
functional glucagon secretion in T2D could be due to the 
decreased insulin levels, as insulin suppresses alpha-cell 
function.105,149 However, islet alpha-cells should have their 
exocytotic function suppressed during the fed state, as intra-
cellular ATP levels should be high as a result.144 However, 
studies have demonstrated that blocking insulin signalling in 
islet alpha-cells in mice results in defective suppression of 
the fed state on glucagon secretion, highlighting the pivotal 
role of insulin in the regulation of the alpha-cell.105,149
Interestingly though, dysregulated glucagon secretion is 
not significant in adolescents with T2D.150 There is some 
evidence that the liver is more sensitive to glucagon in T2D 
patients, further exacerbating the hyperglycaemia, although 
there have been conflicting findings with this observation.142 
Both T1D and T2D induce major changes in the structure of 
animal and human pancreatic islets.141 The changes in the 
islets of T2D patients have been postulated to induce altered 
signalling within the islets, which contributes to the pheno-
type of this disease.141 The increase in alpha-cell mass likely 
results in increased alpha–alpha cell contacts at the expense 
of beta–beta cell contacts, which may alter intra-islet 
signalling.151 The amyloid deposits in the islets have also 
been postulated to alter intra-islet signalling.124 Islet alpha- 
cells are usually found in the periphery of the islets, but in 
diabetes, many of the alpha-cells are found in the centre as 
well; in rodent models, this can be reversed by restoring 
normoglycaemia.141,152 The proportion of delta–delta and 
delta–alpha cell contacts also increases, likely as a result of 
the beta-cell destruction in T2D.151 In T2D rodent models, 
delta-cells were reported to migrate from the periphery of the 
islets to the centre.152 How the morphology, migration and 
number of islet gamma- and epsilon-cells are altered in T2D 
is not well studied.141 Although there have been reports 
suggesting that the delta-cell number is increased in diabetes, 
other studies suggested that the number of these cells was 
unaltered in patients’ islets.153,154 Interestingly, a recent 
study found that the delta-cell number and volume were 
decreased in baboons with impaired fasting glucose by 
~41%, and this was due to apoptosis.155 Evidence is emer-
ging that a subset of islet beta-cells may undergo conversion 
into other endocrine islet cell types in T2D, which may 
account for the increased alpha-cell population observed in 
some T2D patients and their distorted insulin-to-glucagon 
ratios.156 Figure 4 compares pancreatic islet architecture 
between healthy and type 2 diabetic individuals.
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The incretin effect is greatly diminished in T2D where 
GLP-1 and GIP account for <20% of the insulin release 
after glucose ingestion in patients.157 The current consen-
sus in the literature is that GLP-1 and GIP circulation 
levels are comparable between T2D patients and nondia-
betic controls in response to nutrient challenges.158 Hence, 
the diminished incretin effect is due to dysfunctional beta- 
cells.159 GLP-1 infusions can normalise blood glucose 
levels, and GLP-1 analogues are used to treat T2D.3 
However, GIP action is lost in T2D and even infusions 
of GIP that result in supraphysiological concentrations fail 
to elicit a significant insulin secretory response in T2D 
patients.160 Studies have demonstrated that intensive insu-
lin administration treatment results in improved insulin 
secretion from islet beta-cells after GIP infusion.161,162 It 
has been established that hyperglycaemia induces down- 
regulation of GIPR expression in beta-cells, so it is plau-
sible that in this study GIPR expression may have been 
upregulated in these cells due to reducing plasma glucose 
levels.159 Therefore, although it is clear that GIP action is 
lost in T2D it could still have future therapeutic potential 
for treating T2D. GIP action in prediabetes has not been 
established to date, so it is currently not clear if impaired 
GIP action is involved in T2D pathogenesis or manifests 
post-diagnosis.
Additionally, pancreatic neuronal activity is also 
impaired in T2D.163 The pancreas is richly innervated by 
the sympathetic and parasympathetic nervous system.164 The 
cephalic phase of insulin secretion is lost in T2D and gluca-
gon secretion is not suppressed during the fed state.163 This 
implies that if the nervous system does suppress glucagon 
secretion in an insulin-independent manner during the fed 
state in healthy individuals then this is absent in T2D. The 
parasympathetic activity also plays a role in stimulating beta- 
cell proliferation in adult animals, which is at least partly 
regulated by acetylcholine binding to muscarinic receptors 
on beta-cells.164,165 The neuronal activity has also been pos-
tulated to modulate the alpha-cell number.163 This demon-
strates that the nervous system is needed for both islet 
function and islet-cell proliferation when appropriate. 
Parasympathetic and sympathetic nervous systems are 
known to influence endocrine pancreas postnatal 
Figure 4 The difference between pancreatic islet architecture in healthy individuals and individuals with T2D. In healthy individuals, beta-cells are situated centrally and 
peripherally and are the most abundant cell type (~70%). Non-beta cells are found in the periphery of the islets and constitute ~30% of the cell population (20% alpha-cell 
and 10% other cell types). Islet architecture is altered in T2D with a greatly diminished population of beta-cells, more alpha-cells, more delta-cells, migration of alpha- and 
delta-cells into the centre, extracellular amyloid plaque deposits, intracellular IAPP oligomers in beta-cells, and enlarged alpha-cells. The altered architecture in T2D 
produces different intra-islet paracrine signalling which impairs metabolic homeostasis. This figure and information in its legend are with data adapted from Brereton et al.141
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development and plasticity in adult animals.163 
Dysfunctional regulation of the pancreatic islet by the ner-
vous system contributes to the clinical phenotype of T2D, but 
whether or not this occurs before or after T2D diagnosis 
remains elusive, although it is reasonable to assume that it 
does, influencing the altered islet architecture observed in 
T2D.141,163 It has been confirmed that glucose-sensing cells 
in the central nervous system (CNS) are excited by either a 
rise (glucose excited neurons) or decrease (glucose inhibited 
neurons) in plasma glucose levels, and it has been postulated 
that these neurons regulate the sympathetic and parasympa-
thetic branches of the autonomic nervous system, which are 
known to influence insulin and glucagon secretion.163 It is 
likely that the pathology of these central neurons contributes 
to the T2D phenotype and may partly, or even exclusively, 
induce T2D pathogenesis by currently unknown mechan-
isms. One study clearly demonstrated the importance of the 
nervous system’s ability to regulate islet beta-cell number 
and function: GLUT2 neuronal knockout mice exhibited 
impaired glucose-stimulated insulin secretion (GSIS), hyper-
glucagonemia, and decreased beta-cell proliferation and 
mass in comparison to controls.166 Importantly, treatment 
of the control mice with the ganglionic blocker chlorisonda-
mine reduced the proliferation rate of beta-cells by 50%, but 
in GLUT2 neuronal knockout mice, chlorisondamine did not 
further reduce the proliferation rate. This study clearly shows 
that the activity of the neuronal glucose-sensing cells and 
islet alpha- and beta-cells function synergistically to promote 
appropriate plasma insulin and glucagon levels – this syner-
gism is known to be dysfunctional in T2D.163 Figure 5 sum-
marises the differential neural regulation of the pancreas 
between healthy and type 2 diabetic individuals.
The notion that glucolipotoxicity conditions in circula-
tion (associated with obesity) induces islet beta-cell dys-
function has been an attractive area of research.167 A 
number of in vitro studies, using insulin-secreting cells 
Figure 5 Comparing the differential neural regulation of pancreatic islets in healthy and type 2 diabetic individuals. T2D patients do not exhibit the cephalic phase of insulin 
secretion and based on the findings from studies it is possible that dysfunctional neuronal regulation of pancreatic islets contributes to the impaired GSIS, hyperglucagonemia, 
and decreased beta-cell proliferation and mass observed in this disease. This figure and information in its legend are with data adapted from these studies.163,166
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and isolated islets, have found that exposure of islet beta- 
cells to glucolipotoxicity conditions results in impaired 
GSIS, impaired insulin expression, and cell death by 
apoptosis.167,168 Importantly, several of these studies 
have demonstrated that fatty acids do not induce beta- 
cell dysfunction in the absence of elevated glucose, high-
lighting that fatty acids and glucose are not cytotoxic 
independently.168,169 The application of these experiments 
to in vivo situations is questionable as it has been demon-
strated that non-diabetic obese subjects exhibit increased 
insulin secretion and an increase in beta-cell number and 
mass, and islet amyloid deposits are rare in these indivi-
duals as aforementioned in this review. Thus, it is reason-
able to assume that glucolipotoxicity diets do not induce 
beta-cell pathology before the prediabetes phase and pre- 
T2D diagnosis. However, in vivo studies on healthy rats 
have demonstrated similar findings to that of in vitro when 
studying the effects of glucolipotoxicity on insulin 
secretion.170 Given that weight loss and a controlled diet 
improve glycaemic control in overweight T2D patients, it 
seems likely that glucolipotoxicity diets worsen the dis-
ease phenotype post-diagnosis.12 However, attributing 
T2D pathogenesis to glucolipotoxicity diets does not 
explain how individuals with a BMI of under 25 develop 
this disease. To further complicate the issue, data obtained 
from humans in lipid infusion studies have produced con-
flicting results as to whether or not glucolipotoxicity con-
ditions impair or boost insulin secretion.171
Studies conducted by Affourtit and colleagues 
attempted to explain mechanistically how glucolipotoxicity 
conditions might impair GSIS.172,173 Interestingly, they 
have found that the impaired GSIS observed during in 
vitro studies involving exposing pancreatic beta-cell line 
INS-1E to glucolipotoxicity conditions (palmitate + high 
glucose) was found not to be dependent on mitochondrial 
dysfunction.173 From the observations of this study, it 
seems that whatever role glucolipotoxicity may have in 
impairing GSIS in T2D is disconnected from mitochondrial 
dysfunction, which is surprising given the role of the mito-
chondria in ATP and reactive oxygen species (ROS) gen-
eration needed for both phases of insulin secretion.174,175 
The concept of “beta-cell rest” to treat T2D has emerged 
given the observations from both in vitro and in vivo 
studies.98 Isolating islets from diabetic rodents and expos-
ing them to euglycemic conditions for 8–12 h resulted in the 
return of both normal insulin secretory capacity and beta- 
cell function.89 Furthermore, bariatric surgery (which 
results in reduced food intake post-surgery) and low-calorie 
diets can induce T2D remission, which can be viewed as in 
vivo evidence that reducing demand on the beta-cell (ie, 
“beta-cell rest”) improves endogenous insulin secretory 
capacity.98 Administering diazoxide (which inhibits endo-
genous insulin secretion and therefore induces a degree of 
transient “beta-cell rest”) to T2D patients resulted in a 280 
and 500% increase in insulin levels over baseline after 
stimulation tests in T2D low and high beta-cell reserve 
groups, respectively.176 This study provides in vivo evi-
dence that “beta-cell rest” can at least temporarily allow 
insulin secretory capacity recovery, and in vitro studies 
examining the effect of diazoxide on diabetic human islets 
produced similar findings.177 Another in vivo study found 
comparable effects on improved beta-cell function follow-
ing short-term continuous subcutaneous insulin infusion in 
T2D patients that were uncontrolled by conventional oral 
therapies.88 This resulted in near euglycemia being 
achieved in the participants and glycaemic control was 
improved after cessation of insulin infusion. Islet beta-cell 
function tests conducted 2 days after cessation of insulin 
infusion revealed that the peak insulin response was notably 
improved. Reducing demand on the islet beta-cells by 
improving insulin sensitivity through weight loss and/or 
pharmacological means has been reported to improve T2D 
prognosis and delay/prevent pre-diabetic individuals pro-
gressing to T2D, suggesting that inducing “beta-cell rest” to 
even a degree alleviates the pathology that is associated 
with this disease.92,98 Despite the evidence generated by 
both in vitro and in vivo studies supporting that glucolipo-
toxicity impairs beta-cell function, these findings likely do 
not apply to non-obese/overweight diabetic individuals.
UCP2 is a protein present in the beta-cell mitochondria 
inner membrane, which was postulated to dampen GSIS 
by dissipating mitochondrial proton motive force as heat 
(due to its analogy with UCP1), thereby reducing the 
efficiency of ATP production. Approximately 20% of the 
proton leak in beta-cells is thought to occur due to the 
presence of UCP2 .178,179 The detection of this protein in 
islet beta-cells is puzzling as sufficient ATP levels are vital 
for the correct function of these cells, and studies have 
shown that overexpression of UCP2 in isolated beta-cells 
impairs GSIS.180–182 It has been shown that a high proton 
motive force (PMF) results in the production of ROS, and 
as UCP2 activity can lower the PMF by increasing proton 
leak, it can then lower intracellular ROS, as well as 
increased production of ROS, is thought to be at least 
partly dependent on an increased mitochondrial PMF in 
islet beta-cells.180,183–185 As ROS are largely thought to be 
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cytotoxic molecules, it was assumed that the fact UCP2 
attenuates ROS production could mean that this protein 
has a protective role in the cell.32,185,186 This notion had 
led to a debate as to whether or not the presence of UCP2 
in these cells is pathological given its ability to decrease 
ATP production or beneficial given its ability to regulate 
levels of ROS.179 However, it has been demonstrated that 
UCP2 does not appear to regulate GSIS, as palmitate + 
high glucose impaired GSIS to the same extent in INS-1E 
cells with and without UCP2 (UCP2 was knocked down 
via RNAi).187 UCP2 knockdown was shown to only mini-
mally and not significantly increase the coupling efficiency 
(<10%) when INS-1E cells were exposed to 28mM glu-
cose and palmitate. Oddly, it was found that palmitate with 
28 mM glucose dampened the coupling efficiency in 
UCP2 depleted cells more than in UCP2 positive cells. 
Based on these findings, it appears that UCP2 is not 
involved in either GSIS or regulation of the efficiency of 
mitochondrial energy transduction in INS-1E cells in vitro.
It has been postulated that UCP2 may not be an uncou-
pling protein despite its analogy with UCP1, but it likely 
functions as a carbon skeleton exporter from the mitochon-
drial matrix, and there is experimental evidence for this.188 
To further complicate the role of UCP2 in GSIS, in vivo 
studies have found that global UCP2 knockout mice exhibit 
either improved glucose tolerance and GSIS, or unaltered 
glucose tolerance and impaired GSIS depending on their 
genetic background.179,187 Beta-cell specific ablation of 
UCP2 produces glucose-intolerant mice that have increased 
proton gradients across their inner mitochondrial mem-
branes (suggesting that this protein does mediate premature 
proton leak), but oddly, ATP levels and respiration rates are 
unaltered.184 The enhancement of GSIS in the beta-cells of 
these mice was suggested to be due to the increased ROS 
levels associated with UCP2 knockout. The glucose intol-
erance observed in these mice was thought to be due to a 
greater alpha-cell area and higher glucagon content in the 
islets, and glucagon was secreted by alpha-cells even during 
high plasma glucose, suggesting that UCP2 presence in 
beta-cells is necessary to maintain appropriate alpha-cell 
behaviour during the fed state. Affourtit and colleagues 
have demonstrated that mitochondrial function plays an 
important role in cell viability, as palmitate-induced mito-
chondrial superoxide formation results in reduced viability; 
this can be prevented by co-exposure to palmitoleate (an 
unsaturated fatty acid).172 Hence, mitochondrial activity 
during glucolipotoxicity may play an important role in 
beta-cell survival in vitro and in vivo. A critical gap in 
UCP2 research is that studies have not taken into account 
the glutathionylation state of this protein.189 
Glutathionylation and deglutathionylation are thought to 
deactivate and activate proton leak, respectively.189,190 
There is evidence that this post-translational modification 
is regulated by intracellular ROS levels (increased ROS 
causes deglutathionylation and decreased ROS does the 
opposite); hence, it is now relatively well established 
mechanistically how ROS levels can regulate themselves 
in these cells.189,190 It is important that future studies exam-
ining UCP2 activity and levels also monitor glutathionyla-
tion status as well, which could explain any unexpected 
phenotypes. Currently, the role of UCP2 in healthy indivi-
duals and T2D patients is unclear, but if this protein behaves 
pathologically in T2D by inducing decreased ATP produc-
tion, then this could explain the dysfunctional insulin secre-
tion observed. Figure 6 proposes how UCP2 activity and 
quantity alter in T2D.
Glucolipotoxicity conditions induce beta-cell dysfunc-
tion in vitro but it is not clear if this is the case in vivo due 
to the reasons aforementioned. Additionally, GSIS defects 
in vitro do not appear to be attributable to the mitochon-
dria, but this has not been confirmed in vivo, and the role 
of UCP2 and its glutathionylation state in GSIS in vivo is 
currently a source of confusion.
Extrapancreatic Tissues 
Involvement in T2D: Aetiology/ 
Pathogenesis and Post-Diagnosis 
Complications
Whilst it is firmly established that pathological pancreatic 
function and peripheral tissue insulin resistance are central 
to T2D aetiology/pathogenesis, there is increasing evi-
dence that other extrapancreatic pathologies may 
contribute.30,191,192 The diabetic phenotype includes sys-
temic pathology, such as in the CVS, skeletal muscle, 
nervous system (central and peripheral), skin, kidneys 
and gastrointestinal tract (GIT), which further exacerbates 
the disease phenotype and/or induces post-diagnosis 
complications.30,193–195 However, research evidence over 
the last few decades suggests that some of these patholo-
gies manifest during the prediabetic phase and is possibly 
therefore involved in both the disease pathogenesis and 
aetiology.191,192 For example, skin and liver pathology can 
manifest during the prediabetic stage, and even in indivi-
duals with metabolic syndrome before islet beta-cell dys-
function occurs.191,196
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Figure 6 Speculation of how UCP2 activity and quantity is altered in T2D. In healthy individuals: UCP2 levels are basal, UCP2 is glutathionylated, ROS levels are low enough 
so that they do not cause cell damage but the levels are sufficient so that these molecules can amplify insulin secretion, and proton leak exists (~55% of islet beta cells’ 
metabolism is wasted due to proton leak which is not caused by UCP2) but is minimal, so enough of the protons can move down the gradient through ATP synthase to 
generate sufficient ATP levels. In T2D, UCP2 is deglutathionylated (due to increased ROS levels) and upregulated allowing for much greater proton leak. Consequently, the 
majority of the protons prematurely leak through the inner mitochondrial membrane and do not pass through ATP synthase, although there is likely a period before the 
UCP2 deglutathionylation where ATP production occurs, it is unlikely that enough ATP is generated during this time to promote adequate insulin secretion. Hence, overall 
ATP production is impaired in the cell resulting in the inadequate insulin secretion observed in T2D during both the postprandial period and fasting. ROS levels are likely too 
high (leading to cytotoxic damage) during the postprandial period as a result of severe nutrient oversupply to islet beta-cells, due to the enhanced hyperglycaemia and 
hyperlipidaemia in T2D during this period. The excess ROS levels result in UCP2 deglutathionylation and a subsequent dissipated PMF, meaning that ROS formation during 
fasting is impaired and insulin secretion is not amplified by ROS to alleviate the chronic hyperglycaemia and hyperlipidaemia in fasting T2D subjects. Although UCP2 may 
become glutathionylated upon ROS levels decreasing during fasting, this likely reverses during subsequent feeding as ROS levels once again become undesirably high, 
restarting this cycle. This figure and information in its legend are with data adapted from these studies.32,175,178,179,189,190,329,330
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It is firmly established that chronic insulin resistance in 
skeletal muscle of people with T2D contributes to the diabetic 
phenotype and results in poor exercise tolerance.3,197 
However, the altered metabolism of skeletal muscle in patients 
results in a reduced capacity to oxidise fat and promote fat 
storage, which further exacerbates the disease phenotype.192 
This behaviour of skeletal muscle is more pronounced in T2D 
as diabesity patients have a reduced ability to oxidise fat than 
obese-matched controls during exercise.192,198 Impaired 
energy utilisation results in decreased exercise tolerance and 
increased fat storage, which further promotes insulin 
resistance.192 Interestingly, this pathological behaviour of ske-
letal muscle has also been detected in individuals with predia-
betes, suggesting that these alterations may play a role in the 
development of both prediabetes and T2D.192,199 However, 
contradictory to this, some studies have shown that fat oxida-
tion is increased in the muscle of T2D patients.200 Additionally, 
metabolic inflexibility is also characteristic of T2D patients, 
whereby patients’ ability to switch from lipid to carbohydrate 
oxidation during insulin stimulation is impaired, which also 
further contributes to impaired exercise tolerance.192 Obese 
normoglycemic individuals were shown to have better meta-
bolic flexibility than weight-matched T2D patients.201 
However, studies have found that metabolic inflexibility of 
glucose is largely due to defective glucose transport,201,202 
which suggests that skeletal muscle is unable to promote 
sufficient insulin secretion from type 2 diabetic islet-beta 
cells via any signalling mechanisms, in which it likely attempts 
to achieve given its need for increased glucose uptake.3,197 
Additionally, given that metabolic inflexibility can be 
improved by weight loss and exercise, this further supports 
the notion that impaired glucose uptake largely accounts for 
this phenomenon, as these activities result in improved insulin 
sensitivity.203
The phenomenon of metabolic inflexibility has also been 
observed in individuals with prediabetes, implying that this 
may play a role in the aetiology/pathogenesis of both predia-
betes and T2D.204 Mild muscle atrophy is common in middle- 
aged T2D patients and becomes more significant during older 
age and diabetic neuropathy.205,206 Although inflammation and 
chronic insulin resistance are thought to promote muscle atro-
phy in T2D patients,206 it is reasonable to assume that the 
impaired energy utilisation promotes the degradation of intra-
cellular proteins to yield sufficient ATP levels, which would 
contribute to the observed muscle atrophy. Evidence is also 
emerging that type 2 diabetic muscle may have detrimental 
effects on beta-cell function via secretion of myokines into 
circulation: myokine profiles differ between T2D patients and 
controls.207 TNFα secretion from T2D subjects was higher 
than healthy controls,207,208 and one in vitro study has shown 
that this myokine impairs beta-cell function.208 Decreased 
numbers of mitochondria have been observed in the muscle 
cells of T2D patients, which has created the notion that a 
decreased population of mitochondria induces insulin 
resistance.200 However, rodent studies have found that an 
increase in mitochondrial biogenesis occurs concomitantly 
with the development of muscle insulin resistance, implying 
that this notion is incorrect.209,210 This increase in mitochon-
dria is postulated to be an early, transient event that is lost as 
the insulin resistance progresses.211 Furthermore, decreasing 
the mitochondrial population or disrupting mitochondrial func-
tion increases basal and insulin-stimulated glucose uptake into 
rodent skeletal muscle.200
Decreased insulin secretion is known to result in increased 
hepatic glucose production, which contributes to hyperglyce-
mia, but type 2 diabetic livers also exhibit hepatic insulin 
resistance, which further increases glucose production during 
the fasting and postprandial period, giving the liver a direct role 
in contributing to the disease phenotype.192,212 Interestingly, 
insulin-induced suppression of gluconeogenesis and glycogen-
olysis has also been shown to be impaired in individuals with 
prediabetes, suggesting that altered liver function is an impor-
tant component during the initial stages of T2D pathology.191 
The diabetic phenotype promotes fat storage in the liver due to 
elevated fatty acid levels in circulation and ~70% of T2D 
patients develop non-alcoholic fatty liver disease 
(NAFLD).213,214 Elevated plasma lipid levels in T2D result in 
increased delivery of fatty acids to the liver, which is largely 
caused by reduced suppression of lipolysis in adipose tissue due 
to decreased insulin action/secretion in diabetes.213 NAFLD is 
an established risk factor for CVD and so increases the risk of 
cardiovascular complications in T2D patients.214,215 T2D also 
increases the risk of NAFLD progressing to non-alcoholic 
steatohepatitis and subsequent liver cirrhosis.214 The increased 
fat storage in the liver of T2D patients further promotes hepatic 
insulin resistance and induces impaired hepatic fatty acid oxi-
dation, which in turn, further increases hepatic fat storage and 
exacerbation of insulin resistance, which worsens hyperglyce-
mia as a result.213,216
Proinflammatory cytokines, produced by adipose tissue as a 
consequence of obesity, are known to be cytotoxic to beta-cells, 
and they likely contribute to T2D pathogenesis and islet dys-
function post-diagnosis.99,217 There is also evidence that these 
cytokines play a role in the induction of insulin resistance.218 
Thus, the adipose tissue also likely contributes to T2D aetiol-
ogy/pathogenesis, but to what extent remains currently 
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unknown.94 The reduced insulin levels also result in increased 
lipolysis and decreased fat storage in adipocytes, resulting in 
hyperlipidaemia and increased deposition of fat into other 
tissues, such as skeletal muscle and liver.219,220 There is also 
evidence that altered gut microbiota profiles observed in T2D 
patients and overweight subjects also promote systemic inflam-
mation and proinflammatory cytokine production, which is 
thought to encourage the disease pathogenesis and contribute 
to the disease phenotype post-diagnosis.221 T2D patients exhibit 
alterations in bone behaviour, which is believed to increase the 
risk of fracture and promote bone fragility: older adults with 
T2D have up to an 80% increase in the risk of extremity 
fracture.222 Decreased levels of the parathyroid hormone have 
been seen in T2D, indicating decreased bone turnover, and 
increased levels of sclerostin in patients also indicate inhibited 
bone formation.222–224 Decreased insulin-like growth factor 
(IGF)-1 levels in T2D also likely results in decreased bone 
formation in T2D.222–224
Evidence is now emerging that T2D induces premature 
ageing of the CNS, as some (but not all) studies have found 
that patients exhibit impaired cognitive performance and elec-
trophysiological defects in the hippocampus, as well as patho-
logical brain morphological abnormalities – all of which are 
reminiscent of the changes observed during normal ageing.225 
Interestingly, GLP-1R is downregulated in the hypothalamus of 
T2D patients in comparison to healthy controls, suggesting that 
the reduced ability of GLP-1 to induce satiety may contribute to 
the dysfunctional feeding behaviours and metabolic homeosta-
sis observed in these patients.226 Whether or not this down-
regulation occurs before or after T2D diagnosis is unknown.
Peripheral neuropathy is a common complication of T2D, 
and an estimated 50% of patients develop diabetic neuropathy 
after 25 years of being diagnosed.227,228 Neuropathy may result 
from excessive levels of nutrients in circulation (resulting in 
complications such as oxidative damage) and impaired cardio-
vascular function (resulting in complications such as hypoxia), 
discussed in detail elsewhere.228 Diabetic neuropathy can have 
a range of consequences depending on the neurons affected: 
sensory neuropathy results in numbness or pain, motor neuron 
neuropathy results in impaired muscle movement and auto-
nomic neuropathy results in dysfunctional regulation of invo-
luntary activities, such as internal organ function.229,230
A recent study found that activation of preproglucagon 
(PPG) neurons in the brainstem of rodents reduced basal 
hepatic glucose production, enhanced intraperitoneal glu-
cose tolerance, and augmented hepatic insulin sensitivity. 
This suggests that PPG neuron-mediated circuitry has an 
important physiological role in promoting glycaemic 
control and insulin sensitivity and that neuronal activity 
can promote metabolic homeostasis via extrapancreatic 
methods.104 Another recent study found that the activation 
of cholinergic preganglionic neurons in rodents via the 
melanocortin-4 receptor agonist lorcaserin reduced hepatic 
glucose production, increased glucose disposal and 
improved insulin sensitivity.129 Lorcaserin has also been 
reported to improve glycaemic control and induce weight 
loss in obese T2D subjects, and this drug was additionally 
shown to both reduce the risk of prediabetic individuals 
progressing to T2D and increase the likelihood of these 
subjects being able to revert to euglycemia.129,231 Given 
the likely role of these neurons in promoting metabolic 
homeostasis in humans, it is likely that PPG and cholinergic 
preganglionic neuronal activity is impaired or absent in 
T2D, possibly as a result of the disease phenotype, or 
dysfunction of these neurons could occur at an early stage 
and play a role in the disease’s aetiology/pathogenesis.
The diabetic phenotype greatly increases the risk of 
atherosclerotic plaque formation due to dyslipidaemia in 
patients, which results in increased plasma levels of the 
small dense atherogenic form of LDL cholesterol, and 
these molecules can easily penetrate the arterial wall and 
promote atherosclerosis.232 Hyperglycaemia also promotes 
atherosclerosis.233 The chronic inflammatory state asso-
ciated with T2D is also thought to encourage plaque growth 
and formation.232 The impaired insulin secretion and action 
induce pathology in the microvasculature, as nitric oxide 
(NO) production is dependent upon insulin signalling.234 
Chronic NO-deficiency in T2D results in a hyper-con-
stricted state of the microvasculature; therefore, the deliv-
ery of oxygen and nutrients to tissues is impaired, 
contributing to diabetic neuropathies and the poor exercise 
tolerance observed in patients, as well as elevated blood 
pressure.232,235,236 Diabetic autonomic neuropathy (DAN) 
also contributes to dysregulated autoregulation of blood 
flow in the vasculature.237 Also, diabetic patients exhibit 
capillary basement membrane thickening due to chronic 
hyperglycemia, further impairing the exchange between 
the circulation and tissues.232 The excess nutrient levels in 
the circulation in T2D are also thought to damage cells 
throughout the cardiovascular system due to excessive 
ROS production caused by increased metabolism, as a 
result of increased mitochondrial nutrient supply.232,238 
The cardiovascular system in T2D is also in a hypercoagul-
able state and patients are at increased risk of thrombosis as 
a result.232 T2D patients are also at increased risk of heart 
failure due to diabetic cardiomyopathy, where myocardial 
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disease manifests in the absence of any other known CVD, 
likely due to hyperglycemia, microvascular damage and 
autonomic neuropathy associated with diabetes.232,239
Diabetic nephropathy (DN) is the most common cause 
of end-stage renal disease globally, with 10–20% of T2D 
patients developing this disease.195 Kidney pathology can 
result due to nerve and blood vessel damage in this organ 
caused by the diabetic phenotype.195,228,232 The diabetic 
phenotype also promotes DN by inducing pathology in 
kidney cells directly involved with glomerular filtration, 
as, for example, hyperglycemia promotes fibrosis in the 
kidney via inducing activation of specific intracellular 
pathways – the mechanisms by which T2D induces DN 
are reviewed in detail elsewhere.195,240 In addition, urinary 
tract infections are more common in diabetic patients, 
which is at least partly thought to be due to increased 
glucose levels in the urine.241 Figure 7 summarises the 
pathological effects that T2D has on different organs and 
systems throughout the body.
Pharmacological Treatments and 
Lifestyle Changes for T2D
After the T2D diagnosis, initial treatments usually involve 
altering diet and lifestyle, as well as increasing physical 
activity in combination with metformin.3 Metformin 
decreases hepatic glycogenolysis, decreases peripheral tis-
sue insulin resistance, increases GLP-1 postprandial secre-
tion (which augments insulin secretion), and delays 
digestion.8 Exercise and weight loss also reduce insulin 
resistance and reduce the risk of T2D associated post- 
diagnosis complications.242,243 If this treatment regime is 
ineffective at promoting normoglycaemia then sulfonylur-
eas and meglitinides are usually the next treatments tried 
which act as insulin secretagogues.3 Common side effects 
of insulin secretagogues include weight gain and hypogly-
caemia, and these drugs are only usually effective in the 
short term.8 Insulin therapy, in the form of multiple daily 
subcutaneous injections, is effective at lowering plasma 
glucose levels and is usually required in the majority of 
patients when the aforementioned treatment regimens fail, 
but there are several side effects, such as weight gain, 
hypoglycaemia and increased risk of colorectal cancer.3,244 
It has been estimated that 50% of patients require insulin 
therapy within 10 years of T2D diagnosis.245 Recently, 
rodent and human studies have found that orally adminis-
tered insulin could be a viable option to treat T2D. This is 
due to the advent of novel delivery systems that allow oral 
insulin to resist degradation in the GIT, be transported into 
Figure 7 A summary of the pathological effects that T2D has on different organs and systems throughout the body, some of which directly contribute to the disease- 
associated dyslipidaemia/hyperglycaemia and subsequent clinical symptoms. This figure and information in its legend are with data adapted from these studies.94,105,106,111,192– 
195,206,214,219–222,225,228,232,241,326–328,331
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circulation, and then act when desired depending on 
plasma glucose concentration, which is desirable given 
the complications associated with multiple daily invasive 
insulin injections.246–249 Modulating GLP-1R activity is 
the most recent therapy used to treat T2D.3 The first 
therapy is based on the use of DPP-IV inhibitors to delay 
GLP-1 breakdown from its active to inactive form.250 
DPP-IV inhibitors increase GLP-1 levels by 2–3-fold 
over 24 hours and have been shown to significantly 
decrease plasma glucose levels.3 Long-term administration 
of these drugs will likely have adverse effects as this 
enzyme is expressed in many tissues and has a variety of 
functions, but no important side effects have been seen 
after over 10 years of use.3 The efficacy of GLP-1 analo-
gues is generally greater than DPP-IV inhibitors, due to the 
supraphysiological concentrations of GLP-1 achieved after 
administration of the former.251 Hence, the preferred ther-
apy for modulating GLP-1R activity involves the admin-
istration of GLP-1 analogues (exenatide and liraglutide, 
lixisenatide, dulaglutide, albiglutide and semaglutide) to 
T2D patients, which improve glycaemic control by aug-
menting insulin secretion and dampening glucagon secre-
tion, as well as delaying gastric emptying.252,253
Exenatide and liraglutide mimic the endogenous 
GLP-1 activity by binding to GLP-1R on various tis-
sues, but these analogues are resistant to degradation.252 
GLP-1 has a half-life of 1–2 minutes, whereas exenatide 
has a half-life of 3.4–4 hours and liraglutide’s half-life 
is 11–13 hours.3 Hence, these GLP-1 analogues vastly 
prolong the GLP-1 response promoting normoglycaemia 
in T2D patients during fasting and after nutrient 
ingestion. An advantage of using GLP-1R agonists 
(and DPP-IV inhibitors) is that they only mediate their 
insulinotropic effects when glucose levels are elevated, 
meaning that the risk of hypoglycaemia is minimal, and 
these therapies have the lowest reported rates of hypo-
glycaemia for T2D treatments.254 Liraglutide and exena-
tide (synthetic exendin-4) have 97 and 52%, 
respectively, homology with GLP-1.255,256 GLP-1R ago-
nists used in T2D treatment are either derivatives of 
native GLP-1 (liraglutide, albiglutide, semaglutide and 
dulaglutide), which have been modified to be resistant to 
DPP-IV inactivation or derivatives of exendin-4 (exena-
tide, lixisenatide and exenatide-LR).257,258 Exendin-4 
was originally isolated from the saliva of the Gila mon-
ster lizard and is resistant to the action of DPP-IV.257,259 
Key pharmacological and clinical features of clinically 
available GLP-1R agonists are presented in Table 3 and 
Figure 8 compares the amino acid sequence of native 
GLP-1 and the GLP-1 analogues liraglutide and 
exenatide.
These GLP-1 analogues are effective insulinotropic 
agents and successfully suppress glucagon secretion in a 
glucose-dependent manner.260–261 GLP-1 analogues also 
induce weight loss, which is associated with improved T2D 
prognosis.252,262,263 GLP-1R activity is thought to mediate 
weight loss by induction of satiety.3,252 Interestingly, it has 
been shown that chronic liraglutide treatment in diabetic 
mice prevents loss of pancreatic beta-cell mass, increases 
proliferation of the beta-cells and decreases apoptosis after 
alloxan injection.264 Inhibition of the beta-cell apoptosis in 
isolated human pancreatic cells was also reported after 
Table 3 Current Glucagon-Like Peptide 1 Receptor (GLP-1R) Agonists Used in Type 2 Diabetes Therapy
GLP-1R Agonist Generic 
Name (Trade Name)
Dosing Half-Life Administration Required 
Before Meals?
Short-acting
Exenatide (Byetta) Twice daily 2.4 hours Yes
Lixisenatide (Lyxumia) Once-daily 4 hours Yes
Intermediate-acting
Liraglutide (Victoza) Once-daily 12 hours No
Long-acting
Exenatide-LAR (Bydureon) Once weekly 96 hours No
Albiglutide (Tanzeum)* Once weekly 6–8 days No
Dulaglutide (Trulicity) Once weekly 90 hours No
Semaglutide (Ozempic) Once weekly 165–184 hours No
Notes: Adapted with permission from Reed J, Bain S, Kanamarlapudi V. Recent advances in understandingthe role of glucagon-like peptide 1. F1000Research. 2020;9:239.257 
*This product was globally withdrawn in July 2018 for commercial reasons.
https://doi.org/10.2147/DMSO.S319895                                                                                                                                                                                                                               
DovePress                                                                                             
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021:14 3586
Reed et al                                                                                                                                                             Dovepress

















































































liraglutide administration, and the beta-cell proliferation rate 
was increased up to three-fold after incubation for 24 h.265 In 
streptozocin-induced type 1 diabetic rats and isolated human 
pancreatic ducts, exendin-4 treatment has also been shown to 
increase the number of insulin producing cells.266 Side 
effects of GLP-1 analogue administration are dyspepsia and 
nausea, but the effects usually subside after continuous 
administration.3 Additionally, it was implicated that GLP-1 
analogue therapy increased the risk of acute pancreatitis, but 
subsequent studies using larger cohorts did not confirm this 
finding.8,267 However, there is evidence that GLP-1 analo-
gues increase the risk of medullary thyroid cancer, which is a 
cause for concern.268
The development of GIP analogues for T2D treatment 
was initially not a desirable field of research due to GIP 
action being thought to be lost in T2D and GIPs ability to 
augment glucagon secretion.3,261 However, unexpectedly, 
preclinical data from a study in 2013 found that GLP-1/ 
GIP dual agonist treatment induce better glycaemic control 
and body weight reduction in diet-induced-obesity mice 
compared to liraglutide only treated controls.269 Co-agon-
ism of GLP-1R and GR was also shown to reduce body 
weight synergistically in rodent obesity models. These co- 
agonists also improved glycaemic control in humans.269 
Additionally, a recent study found that co-agonism of 
GLP-1R and GR was reported to ameliorate diet-induced 
dyslipidemia and atherosclerosis by increasing energy 
expenditure, reducing liver inflammation and regulating 
bile homeostasis in rodents.270
A recent study found that exenatide increased adiponectin 
secretion from adipose tissue in both in vivo and in vitro 
studies.271 Adiponectin is a peripheral tissue insulin sensitizer, 
and its levels are known to decrease in obese and T2D 
patients.272 This study demonstrated that modulating GLP- 
1R activity has the potential to improve both insulin secretion 
and action in T2D and that GLP-1 analogues may also be able 
to induce weight loss by augmenting adiponectin secretion, as 
well as inducing satiety. GLP-1 analogues are as effective as 
second-line therapy in improving glycaemic control in patients 
with T2D.273 Reductions in glycated haemoglobin from base-
line with GLP-1 analogues tend to be greater than or compar-
able to insulin therapy.262,274 GLP-1 analogues are also 
consistently more effective at inducing weight loss than most 
oral glucose-lowering drugs and insulin.262,263 GLP-1 analo-
gues were also shown to confer lower hypoglycemia risk 
versus insulin or sulfonylureas.262 Additionally, GLP-1 analo-
gues also appear to decrease the risk of cardiovascular pathol-
ogy in patients, according to some studies, and preliminary 
data suggest they do so to a greater degree than other oral 
glucose-lowering drugs.262,275–277 However, two GLP-1 ana-
logues tested in two studies demonstrated no advantage in 
influencing cardiovascular outcome.278,279 Recent systematic 
Figure 8 The amino acid sequence of GLP-1, liraglutide and exenatide. Amino acids highlighted green in exenatide indicate altered amino acids from the GLP-1 sequence. 
The purple amino acids in exenatide indicate amino acids that have been added. The amino acid highlighted red in liraglutide is modified by the addition of palmitic acid 
enabling binding to albumin which results in an increased half-life of liraglutide in circulation. This figure is with data adapted from Lorenz et al.332
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reviews and meta-analyses found that GLP-1R agonists 
reduced major adverse cardiovascular events in T2D 
patients280–282 and also had beneficial effects on kidney 
outcome.283 The reported varying impacts of different GLP- 
1R agonists on blood glucose levels, weight loss, cardiovas-
cular outcomes and adverse effects should play an integral role 
when determining which agonist is best to administer to a 
patient depending on their medical requirements.260
Small Molecule Agonists
Studies have demonstrated that GLP-1R has allosteric agonist 
binding sites and that these sites are distinct from the orthos-
teric agonist (GLP-1) binding site.3 The first allosteric agonist 
identified for GLP-1R was compound 1, which had a low 
affinity and a low potency for GLP-1R.3 Compound 2 was 
then produced, which has been shown to be a more potent 
agonist, and this molecule also increases the affinity of GLP- 
1R for GLP-1.284 Additionally, compound 2 binding was not 
inhibited by the exendin (9–39) antagonist (truncated 
exenatide), demonstrating that this compound binding site on 
GLP-1R is distinct from the orthosteric GLP-1 binding 
site.3,284 However, compound 2 does not stimulate insulin 
secretion to the same extent as GLP-1, liraglutide or exenatide 
in vivo, and combining liraglutide or exenatide with com-
pound 2 did not improve insulin secretion in mice.285 
Compounds A and B have also been shown to demonstrate 
ago-allosteric properties and induce cyclic adenosine mono-
phosphate (cAMP) signalling, as well as increased insulin 
secretion in rat islets and animal studies.3,14 One study showed 
that compound B almost normalised insulin secretion in 
human islets isolated from a T2D donor.286 Compounds 2 
and B bind to a distinct site from the orthosteric binding site, 
as GLP-1R antagonists exendin (9–39) and JANT4, as well as 
the V36A mutation in GLP-1R, did not inhibit cAMP produc-
tion upon compound 2 or B administration.14 Compounds 2 
and B induced cAMP production in human GLP-1R expres-
sing cells but caused no intracellular Ca2+ accumulation, ERK 
Figure 9 The chemical structure of the small molecule allosteric agonists compound 2 and compound B of GLP-1R, which shown schematically with numbered 
transmembrane domains. This figure is adapted with data from these studies.3,14
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phosphorylation or receptor internalisation.14 Prevention of 
receptor internalisation may allow for continuous downstream 
signalling of the receptor, which could, in theory, raise insulin 
levels in T2D patients – this is an area of ongoing research.252 
The K334A mutation (which affects the Gαs coupling) of 
GLP-1R inhibited both GLP-1 and compounds 2 and B 
induced cAMP production, which demonstrates that GLP-1 
and both compounds 2 and B induce similar conformational 
changes needed for the Gαs activation.14 A recent study 
showed that compounds 2 and B bind and covalently modify 
residue 347 in ICL3 of GLP-1R.287 Residues 328, 351 and 335 
of GLP-1R were recently demonstrated to be important for 
compound 2 potency, as mutagenesis of these residues reduced 
compound 2 activity.288 In this same study, enhanced com-
pound 2 potency was demonstrated by GLP-1R when its 
residue 332 was mutated to tryptophan, which is in contrast 
to the effect observed with this mutation on the potency of 
allosteric antagonists. It was postulated that enhanced com-
pound 2 potency was caused by increased hydrophobic inter-
actions between the receptor and the agonist with this 
mutation. Figure 9 shows the chemical structures of com-
pounds 2 and B.
GLP-1R, GIPR and GR Tri-Agonist
In 2015, a triple agonist for GLP-1R, GIPR and GR was 
developed and tested on diet-induced obese (DIO) mice.289 
The tri-agonist lowered body weight in these mice to a 
greater extent than the GLP-1R/GIPR coagonist after 20 
days of treatment. Both the coagonist and tri-agonist did 
not induce hypoglycaemia and were equally effective at 
reducing blood glucose levels and improving glucose tol-
erance, demonstrating that surprisingly chronic GR agon-
ism does not counteract the anti-hyperglycemic effects of 
GLP-1R and GIPR activity. Interestingly, tri-agonist trea-
ted mice had lower plasma insulin levels than the coago-
nist-treated mice, indicating improved insulin sensitivity. 
In theory, chronic GR activation should raise plasma glu-
cose levels and insulin secretion would then need to be 
concomitantly increased to maintain normoglycaemia dur-
ing tri-agonist treatment, but this was not observed in this 
study. Given that there was no difference in food intake 
between wild-type mice treated with the dual-incretin 
GLP-1/GIP coagonist and those treated with the tri-ago-
nist, the greater difference in weight loss was attributed to 
significantly enhanced ATP expenditure in tri-agonist-trea-
ted DIO mice. The capacity of the tri-agonist to prevent 
the development of spontaneous diabetes compared with 
the dual-incretin GLP-1/GIP coagonist was tested in 
mouse models of T2D. Tri-agonist treatment prevented 
the excessive weight gain to a greater extent than the 
coagonist, and this difference was not due to cumulative 
food intake. Additionally, the tri-agonist protected these 
mice from fasting hyperglycaemia to a better degree than 
the coagonist. Interestingly, the tri-agonist also signifi-
cantly reduced pancreatic alpha-cell infiltration into the 
core of pancreatic islets, helping to preserve the islet 
architecture observed in healthy pancreatic islets. The tri- 
agonist was also demonstrated to delay T2D progression in 
rodent models of spontaneous diabetes, as glycaemic 
improvements were maintained in Zucker diabetic fatty 
rats 3 weeks after treatment cessation, even though they 
had gained body weight and were comparable in mass to 
vehicle-treated controls. Given that weight and food intake 
were not altered in lean mice even after chronic treatment 
with the tri-agonist, this demonstrates that the effects of 
the tri-agonist do not manifest in the absence of excessive 
nutrient storage. Another recent study,290 which investi-
gated the effects of other GLP-1, GIP and GR tri-agonist 
in rodents, found that this agonist ameliorated diabetic 
nephropathy-related disorders, as well as reduced body 
weight, food intake and hyperglycaemia. This suggests 
that these tri-agonists have the therapeutic potential to 
alleviate post-diagnosis complications in patients.
Surgical Options for T2D: Bariatric 
Surgery
Bariatric surgery includes a variety of procedures per-
formed on the GIT in people who are severely obese 
(BMI ≥40) or in individuals with a BMI of ≥35 that have 
a condition that can be improved by losing weight such as 
T2D or high blood pressure.291 Weight loss is achieved by 
reducing the size of the stomach with a gastric band or by 
removing a portion of the stomach (sleeve gastrectomy or 
biliopancreatic diversion with duodenal switch), and 
resecting and re-routing the small intestine to a small 
stomach pouch (gastric bypass surgery) is another surgical 
option to promote weight loss.292 Reduction in the size of 
the stomach results in patients experiencing satiety with 
less food and the bypass means that fewer nutrients will be 
ingested as part of the intestine will no longer be involved 
in digestion.291,292 This surgery is only used when other 
options have not been effective for weight reduction, such 
as diet and lifestyle changes.13,291 The obesity epidemic in 
recent decades has been parallelled by an increase in 
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bariatric surgery.292 Longitudinal studies have found that 
this surgery significantly reduces body weight over time, 
improves glycaemic control and prognosis in T2D 
patients, and reduces mortality and risk of obesity-related 
co-morbidities, such as cardiovascular and respiratory 
pathology.291 Data collected globally revealed that the 
number of patients undergoing bariatric surgery rose 
from 40,000 in 1998 to 146,300 in 2003.293
Bariatric surgery is known to be able to induce T2D 
remission, and one study found that 53% of patients were 
in complete T2D remission three years post-surgery and 
another 10% were in partial remission according to the 
American Diabetes Association criteria, although remis-
sion rates vary between the studies, with one study report-
ing that 34% of patients were in complete remission 23 
months post-surgery.294 The consensus in the literature is 
that complete remission rates decrease with time, as 
demonstrated in one study where 43% of patients had 
complete remission after 2 years post-surgery, which 
dropped to 24% after 5 years.294,295 Recent findings sug-
gest that a persistent impairment in insulin secretion is a 
crucial factor in failure to sustain T2D remission after 
bariatric surgery.295–297 The improvements observed in 
post-surgery were originally postulated to be induced by 
the subsequent post-surgery weight loss, but it has become 
apparent that reversal of insulin resistance is induced 
before any significant weight loss occurs.298 Hence, it is 
currently unclear how T2D remission is achieved via bar-
iatric surgery, but it is not just due to the weight loss 
associated with this surgery. In both T2D obese and 
T2D-free obese patients, bariatric surgery increases post-
prandial GLP-1 levels (from up to 3-fold pre-surgery and 
nearly 8-fold vs baseline after gastric bypass).297 
Interestingly, gastric bypass and sleeve gastrectomy have 
been reported to induce similar improvements in glycae-
mic control, despite inferior GLP-1 levels and BMI 
decreased in patients that had undergone sleeve 
gastrectomy.296
A recent study reported that bariatric surgery improves 
disposition index (DI), a score determined by insulin sen-
sitivity times the amount of insulin secreted in response to 
blood glucose levels, in diabetes-free subjects such that 
after 2 years post-surgery, it almost matches general popu-
lation values.297 However, insulin secretion in response to 
intravenously administered glucose declines in these indi-
viduals, implying that the improved DI is a result of the 
enhanced post-surgery GLP-1 plasma levels. In the T2D 
subjects of the same study (91% remission rate at 2 years 
post-surgery), both disposition indices and insulin secre-
tion in response to intravenously administered glucose 
improve 2 years post-surgery but are still notably lower 
than population norms. Fasting plasma glucose levels were 
reported to revert to normal levels 2 years post-surgery in 
over 90% of T2D subjects (from 7.30 to 5.24 mmol), and 
become comparable to non-diabetic subjects (5.00 mmol). 
Although average peak glucose levels remained similar in 
the diabetic group 2 years after surgery (from 9.96 to 
9.79 mmol/L), peak postprandial glucose levels shifted to 
an earlier time point and rapidly declined to within the 
normoglycaemic range, meaning that the time the indivi-
dual was subjected to hyperglycaemia was greatly reduced 
and for the majority of 4 hours following nutrient inges-
tion their plasma glucose levels were in the healthy range. 
Surprisingly, average peak glucose levels increased in non- 
diabetic subjects after surgery, but these individuals simi-
larly had peak levels at an earlier time point, with a 
subsequent more rapid decline in plasma glucose levels. 
Despite this postprandial hyperglycaemia, the overall 
reductions in fasting and postprandial glucose exposure 
following bariatric surgery in nondiabetic individuals are 
thought to be beneficial due to the reported reduced cardi-
ovascular complications associated with post-surgery 
groups compared with non-surgical control groups.297 
Average peak insulin levels were notably lower in diabetic 
subjects (771.4 pmol/L) compared to non-diabetic (1221 
pmol/L) 2 years post-surgery, although average fasting 
insulin levels were higher in diabetic subjects (41.5 vs 
36.9 pmol/L). In both groups, average peak insulin levels 
improved 2 years post-surgery: pre-surgery peak insulin 
levels were 491.9 and 7778.3 pmol/L in the diabetic and 
non-diabetic groups, respectively. Interestingly, although 
the average proinsulin: insulin ratio marginally improved 
2 years after surgery in diabetic subjects (from 2.2 to 1.8), 
it remained notably higher than the value observed in the 
non-diabetic control group (1.1), demonstrating that bar-
iatric surgery does not have much impact on defective 
insulin processing by islet beta-cells. Interestingly, average 
peak postprandial glucagon levels increased in both dia-
betic (from 102.2 to 112.3ng/L) and non-diabetic (from 
99.2 to 109.9 ng/L) groups after surgery, implying a ben-
eficial role of this hormone in promoting post-surgical 
weight loss, and the opposite was the case for fasting 
glucagon levels.
Plasma GLP-1 and GIP responses, as well as insulin 
levels, were augmented in a pattern that mirrored the accel-
erated postprandial glucose appearance and disappearance 
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following surgery in both diabetic and nondiabetic groups. 
Despite the notable benefits and reported metabolic 
improvements, this surgery is expensive and not always 
successful in inducing weight loss. Further, there are 
numerous post-surgery complications, such as vomiting 
and dumping syndrome, iron and B12 deficiency, and sec-
ondary hyperparathyroidism.13 The majority of patients 
develop vomiting and dumping syndrome post-surgery but 
this usually subsides within a year due to patients' GIT and 
feeding behaviours adjusting, and medication is available to 
treat this syndrome if necessary.13 After one year post- 
surgery, ~30% of patients need B12 supplementation to 
maintain normal plasma levels of B12.299 The prevalence 
of B12 deficiency increases in the post-surgery population 
yearly, it has even been reported to be as high as 70% in one 
study in the long term.300 B12 supplementation usually 
treats this post-surgery complication, but a minority of 
patients require monthly intramuscular B12 injections.13 
Iron deficiency is usually only seen in menstruating 
women after one year of post-surgery, and this complication 
can be overcome by intravenous iron infusion several times 
a year.13,301 During weight loss after surgery, many patients 
develop gallstones, and patients that develop gallstone- 
related symptoms undergo surgery to remove the gall 
bladder.13 Secondary hyperparathyroidism is characterised 
by elevated levels of parathyroid hormone caused by exces-
sive activity and hyperplasia of the parathyroid glands.302 
This hormone has catabolic effects on bone tissue and 
increases vitamin D synthesis, which raises the plasma 
calcium levels.303 Bariatric surgery patients often develop 
secondary hyperparathyroidism due to malabsorption of 
calcium from the GIT as a result of the surgery.13 Vitamin 
D and calcium supplementation are effective treatments for 
this post-surgical complication.304 It has been estimated 
that ~29% of patients that undergo bariatric surgery develop 
secondary hyperparathyroidism.13 Thus, it is desirable for a 
treatment to be developed to mimic the effects of bariatric 
surgery but without the aforementioned post-surgery 
complications.
Future Perspectives
Studies have found evidence that GLP-1 exerts multiple 
beneficial extrapancreatic actions on both tissues positive 
and negative for GLP-1R expression,252 and clinical trials 
have found that some GLP-1 mimetic-based therapies 
alleviate cardiovascular pathology associated with 
T2D.305 This implies that the GLP-1R agonists may be 
able to alleviate the systemic pathology that is associated 
with T2D,306–308 and not just be able to augment insulin 
secretion from islet beta-cells of T2D patients.
In addition to augmenting insulin secretion from islet 
beta-cells, both in vivo and in vitro studies have produced 
evidence that GLP-1 action improves islet beta-cell survi-
val and proliferation,252,259 which is also a relevant area of 
research as it is well established that T2D pathology is 
associated with an increased rate of islet beta-cell 
apoptosis.309 Given the reduced population of these cells 
in patients,310 enhanced proliferation would, in theory, be 
desirable to increase plasma insulin levels in patients to 
promote normoglycaemia and normolipidaemia. 
Therefore, comparing how GLP-1R orthosteric and allos-
teric agonists influence islet beta-cell survival is a desir-
able future area of research. Despite controversial 
evidence that islet alpha-cells express GLP-1R, there is 
substantial evidence to suggest that GLP-1 action sup-
presses glucagon secretion, which is also important for 
alleviating T2D pathology, as T2D is now considered to 
be a bi-hormonal disorder.142 Therefore, determining how 
GLP-1R orthosteric and allosteric agonists modulate 
islet alpha-cell activity is another area of future research. 
Finally, to obtain further insight into how orthosteric and 
allosteric GLP-1R agonists can modulate islet beta-cells, it 
will be necessary to determine how these agonists influ-
ence other cells in the pancreatic islets, such as alpha-cells 
and determine how these cells, in turn, may subsequently 
modulate beta-cell activity via paracrine signalling.
GLP-1R orthosteric agonism has been shown to be an 
effective treatment for T2D, and the therapeutic potential 
of GLP-1R allosteric agonism to provide more efficacious 
treatment is an ongoing area of research. Although not 
discussed here, modulating the activity of other cell recep-
tors via allosteric agonism could also yield more effica-
cious therapeutic options for T2D. Modulating the activity 
of multiple receptors (including GLP-1R) simultaneously 
for hormones involved in metabolic homeostasis using a 
unimolecular agonist appears to be a promising new ther-
apeutic option for future T2D treatment, and is an area of 
ongoing research.289,290 Extrapancreatic pathology asso-
ciated with T2D is discussed in this review to highlight 
that this disease has systemic consequences on the body, 
and ideally, treatments should aim to alleviate this sys-
temic pathology via direct mechanisms as well as by 
improving insulin secretion/action; given that GLP-1 tar-
gets multiple organs, GLP-1-based therapies could achieve 
this.252 A recent longitudinal study demonstrated the 
potential of GLP-1R agonism to prevent T2D 
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021:14                                               https://doi.org/10.2147/DMSO.S319895                                                                                                                                                                                                                       
DovePress                                                                                                                       
3591
Dovepress                                                                                                                                                            Reed et al

















































































manifestation in obese individuals and individuals with a 
BMI of >27 that had hypertension or dyslipidaemia: after 
160 weeks, the liraglutide treated group (n=1472) had a 
smaller percentage of the population diagnosed with T2D 
(2% vs 6%) than the placebo-treated control group 
(n=738).311 Additionally, time for T2D onset during the 
160-week study was found to be 2.7x longer in the liraglu-
tide treated group than in the placebo control group. The 
results of this study have important future implications, as 
GLP-1R agonism may not only be an effective treatment 
for T2D but also prevent or delay the disease manifesta-
tion in at-risk individuals. A recent study also found that a 
new GLP-1R agonist, peptide 8, had a greater insulinotro-
pic effect (at 30nM) than GLP-1 on rat islets, and this 
agonist was also shown to have effects similar to exendin- 
4 in mice during an OGTT.312 However, peptide 8 had a 
significant glucose-lowering effect even when it was admi-
nistered 30 min before the OGTT, in contrast to exendin-4, 
due to its extended duration of action. The clinical poten-
tial of peptide 8 is another area of future research, given its 
enhanced insulinotropic activity over GLP-1 and other 
GLP-1R orthosteric agonists tested in this study. Given 
the different structures of GLP-1R agonists, it is plausible 
that how they bind to GLP-1R differs, which subsequently 
produces differential activation of the receptor, explaining 
the observations from studies.288,312 Further understanding 
mechanistically how GLP-1R can be activated differently 
by different orthosteric and allosteric agonists may have 
clinical relevance in the future. Given the conflicting find-
ings observed between human and animal studies investi-
gating the activity of hormones involved in regulating 
metabolic homeostasis (especially GLP-1), it is important 
to note that observations from animal studies may have 
limited clinical implications for developing new T2D 
therapies for humans.257,305
Interestingly, over recent years, it has become increas-
ingly recognised that the aetiology of T2D encompasses 
autoimmune activity, similar to T1D.313 Strikingly, studies 
have demonstrated that islet-reactive T-cells can be found 
in phenotypic human T2D patients, and many studies have 
found that a subset of T2D patients test positive for islet 
beta-cell autoantibodies - these T-cells and antibodies are 
usually associated with T1D pathogenesis.313 One study 
found that 12% of T2D patients screened for islet auto-
antibodies were positive for at least one islet 
autoantibody.314 Staggeringly, islet reactive T-cells were 
found in 72% of phenotypic T2D patients that participated 
in one study, which was an unexpected finding, especially 
as great care was taken to select patients that had minimal 
chance of being misdiagnosed with T2D and have T1D - 
all participants were obese or had an increased waist-to- 
hip ratio, had no history of ketoacidosis, and had not 
received insulin treatment.315 Convincing evidence of 
autoimmunity being involved in T2D pathogenesis was 
also provided by a study that induced B lymphocyte defi-
ciency in New Zealand obese mice (an obese polygenic 
mouse model of obesity and T2D), as B lymphocyte 
deficient mice were found to not develop T2D - this 
implies that B cells may be vital for T2D pathogenesis.316 
Further evidence of B lymphocyte involvement in T2D 
pathogenesis has been provided by the observation that the 
B cells of T2D patients fail to secrete IL-10 (an important 
negative immunoregulatory molecule) after stimulation.317 
The notion that T1D and T2D may not have such distinct 
aetiologies as previously thought is certainly an area for 
future research and is of great interest. If it becomes 
elucidated that T2D does have an autoimmune aetiology 
then it can be classified as a less severe variant of T1D, as 
T2D patients do not exhibit the absolute insulin deficiency 
seen in T1D. Additionally, if both T1D and T2D have 
similar autoimmune aetiologies, understanding why T2D 
patients do not have the T1D clinical phenotype is an 
important area of future research.
A recent study found by using live-cell imaging that 
the ability of insulin vesicles to successfully dock onto the 
plasma membrane correlates with insulin secretion from 
human islet beta-cells and this was shown to be reduced in 
T2D.318 This study found that defective insulin secretion 
in T2D islet beta-cells was caused by a drastically 
decreased rate of successful docking events (docking 
events were found to be 5-fold more frequent in non- 
diabetic beta-cells compared to diabetic beta-cells), rather 
than reduced delivery of insulin vesicles to the plasma 
membrane, which was found to be similar between non- 
diabetic and diabetic beta-cells. Expression analysis found 
that the expression of proteins involved in granule docking 
was downregulated in T2D. Hence, this suggests in T2D 
that defective molecular attachment of insulin vesicles to 
the release site results in inadequate plasma insulin levels 
to promote normoglycaemia, and that the diabetic pheno-
type is not as a result of intracellular insulin content and/or 
the number of insulin vesicles being insufficient in diabetic 
islet beta-cells. Improving islet beta-cell granule docking, 
therefore, represents an attractive and new therapeutic 
target for the development of antidiabetic therapies.
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A recent systematic review and meta-analysis reported 
that using hematopoietic stem cells and mesenchymal stem 
cells derived from bone marrow, placenta or umbilical 
cord tissue to treat T2D is generally safe. The stem cell 
therapy also improves one or more of the following for 
T2D patients: levels of C-peptide, HbA1c, quality of life 
score, and insulin requirements.319–321 However, there 
have been inconsistencies with these findings generated 
in other studies and one study reported severe infections 
in T1D patients after the stem cell therapy.319,322–324 
Additionally, the mechanism by which these stem cells 
exert any positive effects is debated. Also, the studies 
that were used to generate these findings had several 
design flaws with regard to deducing accurate conclusions 
and the total sample size was not large enough.319 The 
encouraging preliminary results from these studies warrant 
validation in larger, randomized, double-blind studies, as 
well as longer follow-up periods to establish the possibility 
of stem cell-based therapies for future T2D treatment.
Conclusion
A better understanding of metabolic homeostasis in healthy 
individuals and the altered metabolic phenotype in T2D will 
likely lead to the development of better treatments for T2D. 
The role of the nervous system, genetics, hormones involved 
in metabolic homeostasis (such as insulin, glucagon, GLP-1 
and GIP), glucolipotoxicity diets and feeding behaviours, 
sedentary lifestyles, altered islet architecture, the immune 
system, altered islet-cell behaviour, UCP2, altered extrapan-
creatic behaviour and risk factors (such as psychological 
stress) have in T2D aetiology and pathogenesis remains to 
be mechanistically understood. Given that T2D is a multi-
factorial disease involving an array of hormones, their recep-
tors and subsequent intracellular activity, future therapeutic 
research needs to take into account how the action of all of 
these hormones interact synergistically in T2D to produce the 
altered metabolic phenotype, and also how treatments such 
as GLP-1R activation-based therapies can influence this hor-
monal synergism to produce a metabolic phenotype more 
similar to that of a healthy individual. GLP-1R agonists are 
an attractive target to generate more effective therapies for 
T2D given that they have been reported to have beneficial 
effects on multiple organs in the body, which are involved in 
disease pathology.
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